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Abstract 28 
Women with chronic kidney disease (CKD) and chronic hypertension (CHT) frequently develop 29 
superimposed pre-eclampsia but distinction from pre-existing disease is challenging. Plasma 30 
placental growth factor (PlGF), B-type natriuretic peptide (BNP), neutrophil gelatinase-associated 31 
lipocalin (NGAL) and serum relaxin concentrations were quantified in a longitudinal prospective 32 
cohort of women with CKD (n=121), CHT (n=44) and healthy controls (n=79) and biomarker 33 
concentrations compared with women with pre-eclampsia without pre-existing disease (n=32). Test 34 
performance was evaluated for diagnosis of superimposed pre-eclampsia requiring delivery within 35 
14 days of sampling. PlGF was evaluated as a promising marker in a validation cohort in a validation 36 
cohort of women with suspected pre-eclampsia (CKD n=29; CHT n=94; superimposed pre-eclampsia 37 
requiring delivery within 14 days n=29) and compared to women without pre-existing disease (No 38 
pre-eclampsia n=290; pre-eclampsia requiring delivery within 14 days n= 176). Between 20
+0
-36
+6
 39 
weeks’ gestation, PlGF had high diagnostic accuracy for superimposed pre-eclampsia requiring 40 
delivery within 14 days (receiver operator characteristic [ROC] 0.85; SE 0.06) and was confirmed 41 
(ROC 0.82; SE 0.06) in the validation cohort. Plasma NGAL, BNP and serum relaxin concentrations 42 
were not discriminatory for superimposed pre-eclampsia.  A low maternal plasma PlGF 43 
concentration could be a useful adjunct to guide decisions regarding admission and delivery for 44 
superimposed pre-eclampsia. 45 
 46 
Key Words: Chronic kidney disease; Endothelium; Proteinuria  47 
  48 
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Introduction 49 
Pre-eclampsia is estimated to complicate 2-8% of all pregnancies;
1
 however superimposed pre-50 
eclampsia is reported to affect approximately 26% of pregnant women with chronic hypertension 51 
(CHT)
2
 and 22-75% of women with chronic kidney disease (CKD).
3
  The diagnosis of pre-eclampsia 52 
when superimposed upon chronic kidney disease (CKD) and chronic hypertension (CHT) is 53 
challenging as it may be clinically indistinguishable from benign gestational progression of pre-54 
existing hypertension and proteinuria, which often coexist.
4
 Superimposed pre-eclampsia is 55 
frequently associated with poor maternal and fetal outcomes. Therefore early and accurate 56 
diagnosis is essential to allow timely intervention, whilst misdiagnosis may also lead to unnecessary 57 
admissions and iatrogenic preterm delivery. 58 
Current hypotheses describe abnormal placental perfusion and predisposing maternal factors
5
 59 
(including cardiac, vascular and renal dysfunction) in the genesis of pre-eclampsia, but the relevant 60 
contribution of placental and maternal influences to development of superimposed pre-eclampsia is 61 
poorly understood. The aims of this study were to evaluate the predictive and diagnostic 62 
performance for superimposed pre-eclampsia of markers of placental, cardiac and renal function 63 
which have previously been implicated in pre-eclampsia in women without underlying disease. 64 
The markers studied were placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor 65 
(sFlt-1), B type natriuretic peptide (BNP), neutrophil gelatinase associated lipocalin (NGAL), and 66 
relaxin. PlGF, an angiogenic protein synthesised by syncytiotrophoblasts increases in the blood of 67 
healthy pregnant women until 26-30 weeks and then fall towards term
6
; low plasma PlGF has been 68 
reported in women with pre-eclampsia.
7
 Conversely sFlt-1, an anti-angiogenic protein which binds to 69 
PlGF preventing interaction with endothelial receptors is raised in women with pre-eclampsia.
8
 70 
Higher than normal concentrations of BNP
9, 10
 are observed in women with pre-eclampsia; BNP is 71 
released with cardiac ventricular strain, and is raised prior to diagnosis in women with early onset 72 
pre-eclampsia.
11
 NGAL , an early marker of acute kidney injury (AKI) has been associated with pre-73 
eclampsia in women without pre-existing disease
12
,
13
 and relaxin is an ovarian hormone known to 74 
play an important physiological role in the renal adaptation to pregnancy.
14
  75 
Measurement of these biomarkers was undertaken in four groups of women with CKD and/or CHT 76 
with superimposed pre-eclampsia; CKD and/or CHT without superimposed pre-eclampsia; pre-77 
eclampsia without CKD and/or CHT and healthy controls. We validated the best performing marker 78 
in a second cohort of women with suspected pre-eclampsia or superimposed pre-eclampsia. The 79 
primary outcome of superimposed pre-eclampsia requiring delivery within 14 days was chosen to 80 
provide a clinically relevant endpoint that reflects current management strategies.
15
     81 
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Results 82 
Longitudinal Cohort 83 
288 women were recruited to the study (Figure 1a). Of those consented, 11 were lost to follow-up 84 
and one was subsequently recruited to a treatment trial for pre-eclampsia. The remaining 276 85 
women provided 471 samples for analysis.   86 
Demographics 87 
Baseline demographic data are presented in Table 1. Details of underlying disease in women with 88 
CKD and/ or CHT are shown in Supplementary Table 2. There were no demographic differences 89 
between women with CKD and/or CHT who did or did not develop superimposed pre-eclampsia.  90 
Demographics for women with CKD and/or CHT according to severity of CKD are shown in 91 
Supplementary Table 3. Twenty-five (21.6%) of 121 women with CKD had the diagnosis of CKD made 92 
during the index pregnancy, including six (26%) of the 23 women with CKD who subsequently 93 
developed superimposed pre-eclampsia. 94 
Maternal outcomes 95 
Maternal outcomes are shown in Table 2.  Forty women (24.2%) were diagnosed with superimposed 96 
pre-eclampsia.  Twenty-three women with CKD (19.0%) developed superimposed pre-eclampsia, 97 
including 8/61 women (13.1%) without secondary CHT, and 15/45 (37.5%) with CHT (P=0.1)), 98 
whereas 12/39 women (30.8%) with primary hypertension developed superimposed pre-eclampsia 99 
(excluding 5 women who were recruited at time of disease).  Only eight women with superimposed 100 
pre-eclampsia (20%) had elevated alanine transaminase (ALT) or low platelets. 101 
Women with superimposed pre-eclampsia were delivered for indications related to its development 102 
including maternal hypertension (n=15; 37.5%), deteriorating renal function (6; 15%), liver 103 
abnormalities (2; 5%), neurological symptoms (2; 5%), fetal indications (10; 25%) and post 37 weeks’ 104 
gestation (2; 5%) and the indication was not clear in two cases (2; 5%).  Forty-four (45%) of 98 105 
women with CKD without superimposed pre-eclampsia had iatrogenic delivery for reasons including 106 
‘deteriorating renal function’ (12; 27%), increasing proteinuria (2; 4.5%), increasing hypertension (2; 107 
4.5%) and the presence of stable CKD (4; 9.0%). Women with CKD and/or CHT had more antenatal 108 
admissions than healthy controls (P<0.0001). Women with superimposed pre-eclampsia were also 109 
more likely to have longer peripartum admissions than women with those without (p<0.0001), but 110 
did not have any more antenatal admissions. 111 
Acute kidney injury 112 
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Overall, 29 (24.2%) women with CKD and 10 (22.7%) women with CHT developed pregnancy 113 
associated sub-acute kidney injury. Women with CKD who developed acute kidney injury, pregnancy 114 
associated sub-acute kidney injury or postpartum progression of renal disease including those who 115 
also met study criteria for superimposed pre-eclampsia are described in Table 3. None of the women 116 
required renal replacement therapy either during or after pregnancy, except one woman already 117 
receiving haemodialysis, and there were no maternal deaths. 118 
Neonatal outcomes 119 
Neonatal outcomes are shown in Table 4. Neonatal outcomes according to underlying presence of 120 
CHT and CKD stage are shown in Supplementary Table 4. 121 
PlGF changes with gestation 122 
Figure 2 shows the gestational profile of PlGF concentrations in 471 samples from 276 women. 123 
Following interval regression (46 left-censored observations, one right-censored) adjusted for 124 
gestation at sampling, women with pre-eclampsia without pre-existing disease had lower PlGF 125 
concentrations (p<0.001) and Z- scores than healthy controls (p<0.001) at all gestational time points. 126 
Women with CKD and/or CHT who subsequently developed superimposed pre-eclampsia had 127 
significantly lower PlGF concentrations adjusted for gestation at sampling than women with CKD 128 
and/or CHT without superimposed pre-eclampsia  (p<0.001). There were no differences in PlGF 129 
concentrations and Z scores between women with CKD and/or CHT with superimposed pre-130 
eclampsia and those with pre-eclampsia without pre-existing disease.   131 
PlGF as predictive marker  132 
Specificities and negative predictive values of PlGF<5
th
 centile for superimposed pre-eclampsia (prior 133 
to onset) were high (>80%); sensitivity was maximal at 25
+0
-28
+6 
weeks (66.7%, 95% CI 22.3-95.7%) 134 
(Supplementary Table 5). 135 
PlGF as diagnostic marker for superimposed pre-eclampsia requiring delivery 136 
Sensitivity and specificity for PlGF for diagnosis of superimposed pre-eclampsia requiring delivery 137 
within 14 days are shown in Table 5, and a threshold of PlGF <5
th
 centile had the best diagnostic 138 
performance. Lower values of plasma PlGF were associated with superimposed pre-eclampsia 139 
requiring delivery within 14 days when assessed between 20
+0
-36
+6 
weeks’ gestation (ROC 0.85, SE 140 
0.06) or between 20
+0
-40
+6 
weeks’ gestation (ROC 0.83, SE 0.08). Subgroup analyses did not reveal 141 
any differences in ROCs between groups at 20
+0
-36
+6 
weeks: CKD alone 0.90 (SE 0.05); CHT alone 0.76 142 
(SE 0.17); CKD with secondary CHT 0.77 (SE 0.17), nor at 20
+0
-40
+6 
weeks: CKD alone 0.93 (SE 0.05); 143 
CHT alone 0.80 (SE 0.09); CKD with secondary CHT 0.78 (0.17). Clinical information relating to 144 
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women with false positive and false negative PlGF concentrations (<5
th
 Centile) at 20
+0
-36
+6 
weeks 145 
are shown in Supplementary Table 6.  Only three women with low PlGF concentrations (1.8%) had 146 
uncomplicated outcomes.  Of the 14 false positive results, three samples were taken before 22 147 
weeks’ gestation with no clinical suspicion of superimposed pre-eclampsia and eight women had 148 
clinical features of superimposed pre-eclampsia but did not meet study criteria for diagnosis and 149 
three women had uncomplicated deliveries.  There were three false negative results including two in 150 
whom clinical suspicion was low, yet increments in blood pressure and proteinuria met study criteria 151 
for diagnosis and one woman with catastrophic antiphospholipid syndrome.    152 
There was no significant difference in test performance at 20-40
+6
 weeks’ for diagnosis of 153 
requirement for delivery for SPE within 14 days between white women (ROC 0.79 (SE 0.09) (n= 7 154 
cases out of 68 women) and black women (ROC 0.90 (SE 0.05) n=7 out of 54 women). Comparison of 155 
PlGF test performance for prediction of preterm delivery <34 weeks’ (ROC 0.66 (SE 0.02)), <37 156 
weeks’ (0.59 (0.07) and SGA <3rd centile (0.71 (0.06)  were lower than for prediction of requirement 157 
for delivery within 14 days for superimposed pre-eclampsia (ROC 0.83 (SE 0.08)).  Further analysis of 158 
the validation cohort was therefore not performed. 159 
BNP, NGAL and relaxin 160 
BNP concentrations were higher in women with pre-eclampsia (p=0.04) and superimposed pre-161 
eclampsia (p<0.0001) than healthy controls, but was not discriminatory in women with CKD and/or 162 
CHT for superimposed pre-eclampsia . NGAL concentrations were higher in women with CKD and/or 163 
CHT with and without superimposed pre-eclampsia than healthy controls (p<0.0001) and was also 164 
non-discriminatory for superimposed pre-eclampsia . Relaxin was undetectable in three women with 165 
ovum donation pregnancies, who were excluded from further analysis. Women with CKD and/or CHT 166 
without superimposed pre-eclampsia had higher relaxin concentrations than healthy controls 167 
(P=0.014) but there were no differences between women with CKD and/or CHT with and without 168 
superimposed pre-eclampsia.   169 
There was no relationship between PlGF, BNP, NGAL or serum relaxin and development of 170 
pregnancy associated sub-acute kidney injury, or deterioration in renal function at six weeks or six 171 
months postpartum. 172 
Associations between markers, and with creatinine 173 
There was no relationship between the PlGF and creatinine concentration, whereas creatinine and 174 
NGAL (R=0.75; P<0.0001) and BNP (R=0.37; P<0.0001) and relaxin (R=0.26; P<0.0001) concentrations 175 
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were significantly correlated.  There was no association between the PlGF concentration and any of 176 
the other markers.  There was no relationship between PlGF centiles and ethnicity. 177 
Uterine and umbilical artery Doppler studies 178 
Diagnostic performance for uterine and umbilical artery Doppler as predictors of the development of 179 
superimposed pre-eclampsia was poor (Supplementary Table 7). 180 
 181 
Validation Cohort 182 
PlGF, the best performing marker for determination of women with superimposed pre-eclampsia 183 
requiring delivery within 14 days, was validated in plasma samples from a second cohort of women 184 
with CKD and/or CHT, and compared to women without pre-existing disease (Figure 1b). Diagnostic 185 
performance of sFlt-1 was additionally evaluated in these women. Baseline demographics and 186 
maternal and neonatal outcomes are shown in Supplementary Tables 8 and 9.   187 
PlGF, sFlt-1 and sFlt-1:PlGF as diagnostic markers 188 
In this second cohort, women with superimposed pre-eclampsia requiring delivery within 14 days 189 
had lower PlGF concentrations and higher sFlt-1 and sFlt-1:PlGF ratios than women with CKD and/or 190 
CHT without superimposed pre-eclampsia(P<0.0001); similarly significant differences in biomarker 191 
concentrations were seen in women with pre-eclampsia compared with women with no pre-existing 192 
disease(P<0.0001). PlGF and sFlt-1 concentrations were not different between women with CKD 193 
and/or CHT and those without pre-existing disease who did not develop superimposed pre-194 
eclampsia or pre-eclampsia, nor was there any difference in concentrations between women with 195 
pre-eclampsia and superimposed pre-eclampsia (Supplementary Table 10). The diagnostic utility of 196 
low PlGF concentrations in women with CKD and/or CHT for superimposed pre-eclampsia requiring  197 
delivery within 14 days for samples taken between 20
+0
-36
+6
 weeks was confirmed (ROC 0.82; SE 198 
0.06) in the validation cohort (Table 6). Diagnostic performance of sFlt-1 was also high (ROC 0.79; SE 199 
0.06) but provided no significant incremental value when evaluated as the sFlt-1/PlGF ratio (0.83; SE 200 
0.06). There were no differences in diagnostic performance of PlGF concentrations, sFlt-1 and sFlt-201 
1:PlGF ratios between women with CKD and/or CHT and women without pre-existing disease 202 
(Supplementary Table 11). Sensitivity and specificity analysis of sFlt1-1: PLGF ratio>85 were 203 
comparable to PlGF <5
th
 centile (Supplementary Table 12). 204 
 205 
Discussion 206 
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The results of this study demonstrate that PlGF concentration has a good diagnostic performance for 207 
superimposed pre-eclampsia  requiring delivery within 14 days in women with CKD and/or CHT (PlGF 208 
(<5
th
 centile) which is comparable to  PlGF test performance for pre-eclampsia in women with no 209 
underlying disease. This observation, being confirmed in a second cohort, provides  promising 210 
evidence for potential use in the clinical setting but requires further validation.  Identification of 211 
superimposed pre-eclampsia  in women with CKD and/or CHT is substantially more challenging than 212 
detecting pre-eclampsia, as worsening hypertension and proteinuria, the conventional diagnostic 213 
parameters, are difficult to interpret when already present in early pregnancy. Furthermore, only 15 214 
out of 173 women (8.7%) with superimposed pre-eclampsia had additional abnormal laboratory 215 
parameters other than serum creatinine. Over a quarter of all women with CKD and/or CHT required 216 
antenatal admission without delivery to investigate for superimposed pre-eclampsia thus confirming 217 
the need for an accurate test. Quantification of PlGF concentrations at time of suspected 218 
superimposed pre-eclampsia in women with CKD and/or CHT may be a useful adjunctive tool to aid 219 
diagnostic uncertainty. 220 
To our knowledge, this study includes the largest reported number of women with CKD and/or CHT 221 
in whom longitudinal and diagnostic analyses of potential biomarkers for superimposed pre-222 
eclampsia have been assessed. Direct comparison of markers with healthy controls and women with 223 
pre-eclampsia without pre-existing conditions enabled assessment of the influence of pre-existing 224 
disease. We found that PlGF and sFlt-1 concentrations in women with CKD and/or CHT follow the 225 
same gestational trajectories as women without pre-existing disease,
16, 17
 supporting a substantial 226 
placental contribution to the development of superimposed pre-eclampsia whereas the association 227 
between maternal cardiac or renal function quantified by BNP, NGAL and relaxin and the onset of 228 
superimposed pre-eclampsia was not of diagnostic potential.  229 
Diagnostic criteria for superimposed pre-eclampsia as written both in guidelines and reported in 230 
pregnancy studies in CKD and/or CHT are ambiguous.
18, 19
 A strength of our study was the use of 231 
robust thresholds for diagnosis. Changes in blood pressure and proteinuria in normal and CKD 232 
pregnancies are well recognised, and therefore the use of arbitrary thresholds of hypertension and 233 
proteinuria is recognised as potentially problematic, and the thresholds chosen are likely to be 234 
imperfect, particularly as some women may have been delivered prior to the development of 235 
parameters of sufficient severity to reach criteria.  However, in the absence of gestational reference 236 
ranges that accurately reflect anticipated fold changes in blood pressure and proteinuria for women 237 
with CKD and/or CHT this method was chosen for confirmation of superimposed pre-eclampsia, as 238 
reflected in the international definitions. Only three of 161 women with CKD and/or CHT with false 239 
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positive results had clinical courses which were uncomplicated. Importantly, the findings of our 240 
study suggest that PlGF concentrations might be used to define superimposed pre-eclampsia in the 241 
future, thus reducing the need for interpretation of ambiguous clinical parameters. 242 
PlGF in the urine of pregnant women mirrors the plasma concentration
20
 but accumulation of 243 
plasma PlGF in women with reduced renal function could confound interpretation of plasma PlGF. 244 
However, the absence of a correlation between PlGF and serum creatinine renders this unlikely, 245 
although as the number of women with severe CKD was few, this requires further assessment. 246 
Two studies which included small numbers of women with chronic glomerulonephritis (n=15 and 247 
n=35) have suggested previously that PlGF and sFlt-1 may be useful markers for superimposed pre-248 
eclampsia
21, 22
 but a strength of the present, much larger study, is the demonstration of usefulness of 249 
PlGF across a spectrum of CKD aetiologies. Others report that PlGF and sFlt-1 concentrations 250 
discriminated between 34 women with pre-eclampsia (without pre-existing risk factors) and 23 251 
women with CKD without superimposed pre-eclampsia but, unlike the present study women with 252 
superimposed pre-eclampsia were not investigated.
23
 Longitudinal studies, confined to women with 253 
CHT, also report low PlGF and high sFlt-1 concentrations prior to onset and time of diagnosis of 254 
superimposed pre-eclampsia
24,25, 26
 but findings have not been validated in a second cohort as 255 
reported here. Only one study of 313 women with CHT found no differences in PlGF in women with 256 
and without superimposed pre-eclampsia,
27
 despite the cohort having a similar demographic profile 257 
and timing of delivery as the present study; the reasons for these discrepant results are unclear.  258 
In our study one in five (20.4%) women with CKD without superimposed pre-eclampsia was 259 
delivered for other renal related indications including the presence of stable CKD. If confirmed by 260 
further validation, high PlGF concentrations may reduce clinician anxiety and therefore the incidence 261 
of unnecessary admission and preterm iatrogenic delivery due to uncertainty over the clinical 262 
significance of gestational change.  However, a limitation of this study is the number of women with 263 
advanced disease and further study of PlGF in this population is needed. Markers of cardiac and 264 
renal function were not predictive or diagnostic of superimposed pre-eclampsia. Further 265 
haemodynamic assessments in women with CKD and/or CHT are needed to determine the 266 
contribution of pre-existing cardiac and vascular disease to the development of superimposed pre-267 
eclampsia.  In contrast with another report of high specificity of Doppler studies in pregnant women 268 
with CKD,
28
 predictive performance of artery Doppler for prediction of superimposed pre-eclampsia 269 
was poor but may have been limited by non-standardised methods of measurements, frequency and 270 
number of scans performed.   271 
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Conclusions 272 
The findings of this study support the role of PlGF as a diagnostic test for superimposed pre-273 
eclampsia requiring delivery within 14 days for women with CKD and/or CHT, and suggest that 274 
impaired placental function rather than pre-existing maternal disease alone is a major contributor to 275 
the development of superimposed pre-eclampsia. Further investigation of the influence of pre-276 
existing maternal disease on the process of early placentation is required.  277 
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Methods 278 
Longitudinal cohort 279 
Women were prospectively enrolled from two London Academic Health Science Centres (Imperial 280 
College and King’s Health Partners) between June 2009 and September 2013. Ethical approval was 281 
provided by the National Research Ethics Service (NRES) (11/LO/1776) and the study was performed 282 
in accordance with the guidelines of the Declaration of Helsinki. Demographic information was 283 
recorded following written informed consent. Venous blood samples were taken up to four times 284 
during pregnancy and serum and plasma stored at -80
o
C. Maternal and perinatal outcome data were 285 
obtained by case note review after delivery.  Definitions for study entry, and outcomes are based on 286 
International Society of Study of Hypertension in Pregnancy guidelines
29
 (Supplementary Table 1).  287 
The following women were recruited i) women with CKD and/or CHT who did and did not develop 288 
superimposed pre-eclampsia  ii) healthy controls iii) women with pre-eclampsia at time of disease 289 
(without pre-existing disease) iv) women with superimposed pre-eclampsia at time of disease, if they 290 
had not already been recruited longitudinally. 291 
The most recent serum creatinine prior to pregnancy was recorded, and for women with no 292 
measurement available an approximation of eGFR before pregnancy was made by increasing the 293 
first recorded antenatal creatinine by 25% and calculation of eGFR by Modified Diet in Renal Disease 294 
calculation
30
  an approach previously used by others.
3
 Uterine and umbilical artery Doppler studies 295 
were recorded for women with CKD and/or CKD, and the predictive value for development of 296 
superimposed pre-eclampsia of mean uterine artery Doppler pressure indices >1.4 and bilateral 297 
notches at 20-24
+6
 weeks’ and umbilical artery indices >95
th
 centile at >28 weeks’ gestation and 298 
within 14 days of delivery were analysed.  All data and final diagnoses were entered by one 299 
researcher, confirmed by a second reviewer, and for complex cases, the diagnosis was adjudicated 300 
by a third senior reviewer, all without access to study (biomarker) results.  301 
Acute kidney injury was defined as a 50% increase in serum creatinine within one week.
31
 Pregnancy 302 
associated sub-acute kidney injury was defined as a 50% increase in serum creatinine from the 303 
lowest recorded value. Birth-weight was assessed by customised birthweight percentile (gestation 304 
related Optimal Weight),
32
 and small for gestational age (SGA) reported as <3
rd
 and <5
th
 centile. 305 
Validation cohort 306 
Women requiring assessment for suspected pre-eclampsia were enrolled in a longitudinal cohort 307 
study approved by NRES (Ref 10/H0701/117), between January 2011 and February 2012 from seven 308 
consultant-led units in the UK and Ireland, and women with CKD and/or CHT or no pre-existing 309 
disease selected. Details have been described previously.
15
  All samples were taken at time of 310 
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suspected disease in order to assess the diagnostic performance of the test at time of presentation 311 
and were categorised according to outcome at delivery. 312 
Assay analyses 313 
Plasma samples were tested without awareness of clinical outcomes, using the Triage PlGF Tests and 314 
CardioRenal (BNP, NGAL) Test (Alere, San Diego CA) according to the manufacturer’s instructions. 315 
The assays use fluorescently labelled recombinant murine monoclonal antibodies (PlGF, BNP) or 316 
recombinant monoclonal antibodies (NGAL), detecting the biomarkers specifically and quantitatively 317 
within certain ranges (PlGF 12-3000 pg/ml; BNP 5-5000 pg/ml; NGAL 15-1300 pg/ml). The total 318 
precision (coefficient of variation) on plasma controls for PlGF at concentrations of 85 and 1300 319 
pg/ml is 12.8% and 13.2% respectively; for BNP at concentrations of 78 and 3450 pg/ml is 9.2% and 320 
13.9% respectively; for NGAL at concentrations of 98 and 1280 ng/ml is 12.5% and 13.5% 321 
respectively based on the manufacturer’s package inserts generated before the study.   322 
Serum relaxin was quantified using a specific enzyme-linked immunosorbent assay kit according to 323 
the manufacturer’s protocol (R&D Systems, Inc., Minneapolis, MN, USA), with an  assay range of 324 
7.81-500 pg/ml, sensitivity of 4.57 pg/ml and inter and intra-assay coefficients of variation of 3.8% 325 
and 4.3% respectively.   326 
sflt-1 was quantified with a Luminex sandwich assay (Alere, San Diego CA), using  a mouse-derived 327 
recombinant Fab conjugated to a magnetic bead as the capture, and a biotin-conjugated 328 
recombinant Fab as the assay detection, optimised for use in Luminex xMap technology (Alere, San 329 
Diego). The assay range was 0.006-27.87 pg/ml and coefficient of variation 10%.    330 
Statistical analysis 331 
Normality of distribution was explored using a Q-Q plot, and logarithmic transformations used 332 
where appropriate. Demographic data are presented as medians (interquartile range) (as not 333 
normally distributed) or frequencies (percentages). Mann-Whitney, and Fisher’s exact test were 334 
used to test differences between groups.  T-tests were used to test differences between biomarkers 335 
following logarithmic transformation to a normal distribution. PlGF concentrations greater than 19 336 
weeks were transformed into a PlGF centile 
33
 and z-scores calculated. To avoid multiple testing, 337 
data were corrected for the inclusion of women who had provided several samples throughout the 338 
same pregnancy, using interval regression analysis with random-effect modelling for individual 339 
clustering.
34
 Interval regression also allows samples measured as below (above) the lower (upper) 340 
limit of detection to be treated as being in an appropriate range, rather than replacing them with a 341 
single number.  The last visit for each woman of the longitudinal cohort taken after 20 weeks’ 342 
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gestation was included for analysis of diagnostic performance of the primary outcome 343 
(superimposed pre-eclampsia requiring delivery within 14 days). Test performance was evaluated as 344 
sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios 345 
and receiver operator characteristic (ROC) in both cohorts for PlGF <5
th
 Centile and sFlt-1:PlGF ratio 346 
>85 as described by others.
 12,31
Spearman’s rank correlations were performed on the last sample 347 
taken from each woman in order to prevent confounding by frequent sampling within an individual. 348 
Statistical analysis was performed in the statistical package Stata (Version 13) and IBM Statistical 349 
Package for the Social Sciences (SPSS) (Version 21).  The study is reported in accordance with 350 
STAndards for the Reporting of Diagnostic accuracy studies (STARD) guidelines. 351 
Sample size calculation 352 
With 29 cases and 94 controls in the validation set, an unbiased estimate can be obtained within 353 
15% of the true sensitivity and within 8% of the true specificity using 95% confidence intervals 354 
around values of 80% sensitivity and specificity.  355 
Role of the funding source 356 
This was an investigator-led study; the funder had no role in study design, patient recruitment, data 357 
collection, analysis, interpretation, nor in writing of the manuscript or decision to submit for 358 
publication.  359 
Disclosure 360 
KB, PTS, LL, CNP, CG, PW, LP and LC report no conflicts.  361 
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Titles and Legends 461 
Figure 1a: Longitudinal Cohort – Flow Diagram of participants 462 
Figure 1b: Validation Cohort – Flow Diagram of participants 463 
Figure 2: Placental growth factor concentrations in healthy controls, women with CHT and/or CKD 464 
with and without superimposed pre-eclampsia in a longitudinal cohort and in women with time of 465 
disease pre-eclampsia according to gestation in weeks 466 
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Abstract 28 
Women with chronic kidney disease (CKD) and chronic hypertension (CHT) frequently develop 29 
superimposed pre-eclampsia but distinction from pre-existing disease is challenging. Plasma 30 
placental growth factor (PlGF), B-type natriuretic peptide (BNP), neutrophil gelatinase-associated 31 
lipocalin (NGAL) and serum relaxin concentrations were quantified in a longitudinal prospective 32 
cohort of women with CKD (n=121), CHT (n=44) and healthy controls (n=79) and biomarker 33 
concentrations compared with women with pre-eclampsia without pre-existing disease (n=32). Test 34 
performance was evaluated for diagnosis of superimposed pre-eclampsia requiring delivery within 35 
14 days of sampling. PlGF was evaluated as a promising marker in a validation cohort in a validation 36 
cohort of women with suspected pre-eclampsia (CKD n=29; CHT n=94; superimposed pre-eclampsia 37 
requiring delivery within 14 days n=29) and compared to women without pre-existing disease (No 38 
pre-eclampsia n=290; pre-eclampsia requiring delivery within 14 days n= 176). Between 20
+0
-36
+6
 39 
weeks’ gestation, PlGF had high diagnostic accuracy for superimposed pre-eclampsia requiring 40 
delivery within 14 days (receiver operator characteristic [ROC] 0.85; SE 0.06) and was confirmed 41 
(ROC 0.82; SE 0.06) in the validation cohort. Plasma NGAL, BNP and serum relaxin concentrations 42 
were not discriminatory for superimposed pre-eclampsia.  A low maternal plasma PlGF 43 
concentration could be a useful adjunct to guide decisions regarding admission and delivery for 44 
superimposed pre-eclampsia. 45 
 46 
Key Words: Chronic kidney disease; Endothelium; Proteinuria  47 
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Introduction 49 
Pre-eclampsia is estimated to complicate 2-8% of all pregnancies;
1
 however superimposed pre-50 
eclampsia is reported to affect approximately 26% of pregnant women with chronic hypertension 51 
(CHT)
2
 and 22-75% of women with chronic kidney disease (CKD).
3
  The diagnosis of pre-eclampsia 52 
when superimposed upon chronic kidney disease (CKD) and chronic hypertension (CHT) is 53 
challenging as it may be clinically indistinguishable from benign gestational progression of pre-54 
existing hypertension and proteinuria, which often coexist.
4
 Superimposed pre-eclampsia is 55 
frequently associated with poor maternal and fetal outcomes. Therefore early and accurate 56 
diagnosis is essential to allow timely intervention, whilst misdiagnosis may also lead to unnecessary 57 
admissions and iatrogenic preterm delivery. 58 
Current hypotheses describe abnormal placental perfusion and predisposing maternal factors
5
 59 
(including cardiac, vascular and renal dysfunction) in the genesis of pre-eclampsia, but the relevant 60 
contribution of placental and maternal influences to development of superimposed pre-eclampsia is 61 
poorly understood. The aims of this study were to evaluate the predictive and diagnostic 62 
performance for superimposed pre-eclampsia of markers of placental, cardiac and renal function 63 
which have previously been implicated in pre-eclampsia in women without underlying disease. 64 
The markers studied were placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor 65 
(sFlt-1), B type natriuretic peptide (BNP), neutrophil gelatinase associated lipocalin (NGAL), and 66 
relaxin. PlGF, an angiogenic protein synthesised by syncytiotrophoblasts increases in the blood of 67 
healthy pregnant women until 26-30 weeks and then fall towards term
6
; low plasma PlGF has been 68 
reported in women with pre-eclampsia.
7
 Conversely sFlt-1, an anti-angiogenic protein which binds to 69 
PlGF preventing interaction with endothelial receptors is raised in women with pre-eclampsia.
8
 70 
Higher than normal concentrations of BNP
9, 10
 are observed in women with pre-eclampsia; BNP is 71 
released with cardiac ventricular strain, and is raised prior to diagnosis in women with early onset 72 
pre-eclampsia.
11
 NGAL , an early marker of acute kidney injury (AKI) has been associated with pre-73 
eclampsia in women without pre-existing disease
12
,
13
 and relaxin is an ovarian hormone known to 74 
play an important physiological role in the renal adaptation to pregnancy.
14
  75 
Measurement of these biomarkers was undertaken in four groups of women with CKD and/or CHT 76 
with superimposed pre-eclampsia; CKD and/or CHT without superimposed pre-eclampsia; pre-77 
eclampsia without CKD and/or CHT and healthy controls. We validated the best performing marker 78 
in a second cohort of women with suspected pre-eclampsia or superimposed pre-eclampsia. The 79 
primary outcome of superimposed pre-eclampsia requiring delivery within 14 days was chosen to 80 
provide a clinically relevant endpoint that reflects current management strategies.
15
     81 
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Results 82 
Longitudinal Cohort 83 
288 women were recruited to the study (Figure 1a). Of those consented, 11 were lost to follow-up 84 
and one was subsequently recruited to a treatment trial for pre-eclampsia. The remaining 276 85 
women provided 471 samples for analysis.   86 
Demographics 87 
Baseline demographic data are presented in Table 1. Details of underlying disease in women with 88 
CKD and/ or CHT are shown in Supplementary Table 2. There were no demographic differences 89 
between women with CKD and/or CHT who did or did not develop superimposed pre-eclampsia.  90 
Demographics for women with CKD and/or CHT according to severity of CKD are shown in 91 
Supplementary Table 3. Twenty-five (21.6%) of 121 women with CKD had the diagnosis of CKD made 92 
during the index pregnancy, including six (26%) of the 23 women with CKD who subsequently 93 
developed superimposed pre-eclampsia. 94 
Maternal outcomes 95 
Maternal outcomes are shown in Table 2.  Forty women (24.2%) were diagnosed with superimposed 96 
pre-eclampsia.  Twenty-three women with CKD (19.0%) developed superimposed pre-eclampsia, 97 
including 8/61 women (13.1%) without secondary CHT, and 15/45 (37.5%) with CHT (P=0.1)), 98 
whereas 12/39 women (30.8%) with primary hypertension developed superimposed pre-eclampsia 99 
(excluding 5 women who were recruited at time of disease).  Only eight women with superimposed 100 
pre-eclampsia (20%) had elevated alanine transaminase (ALT) or low platelets. 101 
Women with superimposed pre-eclampsia were delivered for indications related to its development 102 
including maternal hypertension (n=15; 37.5%), deteriorating renal function (6; 15%), liver 103 
abnormalities (2; 5%), neurological symptoms (2; 5%), fetal indications (10; 25%) and post 37 weeks’ 104 
gestation (2; 5%) and the indication was not clear in two cases (2; 5%).  Forty-four (45%) of 98 105 
women with CKD without superimposed pre-eclampsia had iatrogenic delivery for reasons including 106 
‘deteriorating renal function’ (12; 27%), increasing proteinuria (2; 4.5%), increasing hypertension (2; 107 
4.5%) and the presence of stable CKD (4; 9.0%). Women with CKD and/or CHT had more antenatal 108 
admissions than healthy controls (P<0.0001). Women with superimposed pre-eclampsia were also 109 
more likely to have longer peripartum admissions than women with those without (p<0.0001), but 110 
did not have any more antenatal admissions. 111 
Acute kidney injury 112 
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Overall, 29 (24.2%) women with CKD and 10 (22.7%) women with CHT developed pregnancy 113 
associated sub-acute kidney injury. Women with CKD who developed acute kidney injury, pregnancy 114 
associated sub-acute kidney injury or postpartum progression of renal disease including those who 115 
also met study criteria for superimposed pre-eclampsia are described in Table 3. None of the women 116 
required renal replacement therapy either during or after pregnancy, except one woman already 117 
receiving haemodialysis, and there were no maternal deaths. 118 
Neonatal outcomes 119 
Neonatal outcomes are shown in Table 4. Neonatal outcomes according to underlying presence of 120 
CHT and CKD stage are shown in Supplementary Table 4. 121 
PlGF changes with gestation 122 
Figure 2 shows the gestational profile of PlGF concentrations in 471 samples from 276 women. 123 
Following interval regression (46 left-censored observations, one right-censored) adjusted for 124 
gestation at sampling, women with pre-eclampsia without pre-existing disease had lower PlGF 125 
concentrations (p<0.001) and Z- scores than healthy controls (p<0.001) at all gestational time points. 126 
Women with CKD and/or CHT who subsequently developed superimposed pre-eclampsia had 127 
significantly lower PlGF concentrations adjusted for gestation at sampling than women with CKD 128 
and/or CHT without superimposed pre-eclampsia  (p<0.001). There were no differences in PlGF 129 
concentrations and Z scores between women with CKD and/or CHT with superimposed pre-130 
eclampsia and those with pre-eclampsia without pre-existing disease.   131 
PlGF as predictive marker  132 
Specificities and negative predictive values of PlGF<5
th
 centile for superimposed pre-eclampsia (prior 133 
to onset) were high (>80%); sensitivity was maximal at 25
+0
-28
+6 
weeks (66.7%, 95% CI 22.3-95.7%) 134 
(Supplementary Table 5). 135 
PlGF as diagnostic marker for superimposed pre-eclampsia requiring delivery 136 
Sensitivity and specificity for PlGF for diagnosis of superimposed pre-eclampsia requiring delivery 137 
within 14 days are shown in Table 5, and a threshold of PlGF <5
th
 centile had the best diagnostic 138 
performance. Lower values of plasma PlGF were associated with superimposed pre-eclampsia 139 
requiring delivery within 14 days when assessed between 20
+0
-36
+6 
weeks’ gestation (ROC 0.85, SE 140 
0.06) or between 20
+0
-40
+6 
weeks’ gestation (ROC 0.83, SE 0.08). Subgroup analyses did not reveal 141 
any differences in ROCs between groups at 20
+0
-36
+6 
weeks: CKD alone 0.90 (SE 0.05); CHT alone 0.76 142 
(SE 0.17); CKD with secondary CHT 0.77 (SE 0.17), nor at 20
+0
-40
+6 
weeks: CKD alone 0.93 (SE 0.05); 143 
CHT alone 0.80 (SE 0.09); CKD with secondary CHT 0.78 (0.17). Clinical information relating to 144 
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women with false positive and false negative PlGF concentrations (<5
th
 Centile) at 20
+0
-36
+6 
weeks 145 
are shown in Supplementary Table 6.  Only three women with low PlGF concentrations (1.8%) had 146 
uncomplicated outcomes.  Of the 14 false positive results, three samples were taken before 22 147 
weeks’ gestation with no clinical suspicion of superimposed pre-eclampsia and eight women had 148 
clinical features of superimposed pre-eclampsia but did not meet study criteria for diagnosis and 149 
three women had uncomplicated deliveries.  There were three false negative results including two in 150 
whom clinical suspicion was low, yet increments in blood pressure and proteinuria met study criteria 151 
for diagnosis and one woman with catastrophic antiphospholipid syndrome.    152 
There was no significant difference in test performance at 20-40
+6
 weeks’ for diagnosis of 153 
requirement for delivery for SPE within 14 days between white women (ROC 0.79 (SE 0.09) (n= 7 154 
cases out of 68 women) and black women (ROC 0.90 (SE 0.05) n=7 out of 54 women). Comparison of 155 
PlGF test performance for prediction of preterm delivery <34 weeks’ (ROC 0.66 (SE 0.02)), <37 156 
weeks’ (0.59 (0.07) and SGA <3rd centile (0.71 (0.06)  were lower than for prediction of requirement 157 
for delivery within 14 days for superimposed pre-eclampsia (ROC 0.83 (SE 0.08)).  Further analysis of 158 
the validation cohort was therefore not performed. 159 
BNP, NGAL and relaxin 160 
BNP concentrations were higher in women with pre-eclampsia (p=0.04) and superimposed pre-161 
eclampsia (p<0.0001) than healthy controls, but was not discriminatory in women with CKD and/or 162 
CHT for superimposed pre-eclampsia . NGAL concentrations were higher in women with CKD and/or 163 
CHT with and without superimposed pre-eclampsia than healthy controls (p<0.0001) and was also 164 
non-discriminatory for superimposed pre-eclampsia . Relaxin was undetectable in three women with 165 
ovum donation pregnancies, who were excluded from further analysis. Women with CKD and/or CHT 166 
without superimposed pre-eclampsia had higher relaxin concentrations than healthy controls 167 
(P=0.014) but there were no differences between women with CKD and/or CHT with and without 168 
superimposed pre-eclampsia.   169 
There was no relationship between PlGF, BNP, NGAL or serum relaxin and development of 170 
pregnancy associated sub-acute kidney injury, or deterioration in renal function at six weeks or six 171 
months postpartum. 172 
Associations between markers, and with creatinine 173 
There was no relationship between the PlGF and creatinine concentration, whereas creatinine and 174 
NGAL (R=0.75; P<0.0001) and BNP (R=0.37; P<0.0001) and relaxin (R=0.26; P<0.0001) concentrations 175 
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were significantly correlated.  There was no association between the PlGF concentration and any of 176 
the other markers.  There was no relationship between PlGF centiles and ethnicity. 177 
Uterine and umbilical artery Doppler studies 178 
Diagnostic performance for uterine and umbilical artery Doppler as predictors of the development of 179 
superimposed pre-eclampsia was poor (Supplementary Table 7). 180 
 181 
Validation Cohort 182 
PlGF, the best performing marker for determination of women with superimposed pre-eclampsia 183 
requiring delivery within 14 days, was validated in plasma samples from a second cohort of women 184 
with CKD and/or CHT, and compared to women without pre-existing disease (Figure 1b). Diagnostic 185 
performance of sFlt-1 was additionally evaluated in these women. Baseline demographics and 186 
maternal and neonatal outcomes are shown in Supplementary Tables 8 and 9.   187 
PlGF, sFlt-1 and sFlt-1:PlGF as diagnostic markers 188 
In this second cohort, women with superimposed pre-eclampsia requiring delivery within 14 days 189 
had lower PlGF concentrations and higher sFlt-1 and sFlt-1:PlGF ratios than women with CKD and/or 190 
CHT without superimposed pre-eclampsia(P<0.0001); similarly significant differences in biomarker 191 
concentrations were seen in women with pre-eclampsia compared with women with no pre-existing 192 
disease(P<0.0001). PlGF and sFlt-1 concentrations were not different between women with CKD 193 
and/or CHT and those without pre-existing disease who did not develop superimposed pre-194 
eclampsia or pre-eclampsia, nor was there any difference in concentrations between women with 195 
pre-eclampsia and superimposed pre-eclampsia (Supplementary Table 10). The diagnostic utility of 196 
low PlGF concentrations in women with CKD and/or CHT for superimposed pre-eclampsia requiring  197 
delivery within 14 days for samples taken between 20
+0
-36
+6
 weeks was confirmed (ROC 0.82; SE 198 
0.06) in the validation cohort (Table 6). Diagnostic performance of sFlt-1 was also high (ROC 0.79; SE 199 
0.06) but provided no significant incremental value when evaluated as the sFlt-1/PlGF ratio (0.83; SE 200 
0.06). There were no differences in diagnostic performance of PlGF concentrations, sFlt-1 and sFlt-201 
1:PlGF ratios between women with CKD and/or CHT and women without pre-existing disease 202 
(Supplementary Table 11). Sensitivity and specificity analysis of sFlt1-1: PLGF ratio>85 were 203 
comparable to PlGF <5
th
 centile (Supplementary Table 12). 204 
 205 
Discussion 206 
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The results of this study demonstrate that PlGF concentration has a good diagnostic performance for 207 
superimposed pre-eclampsia  requiring delivery within 14 days in women with CKD and/or CHT (PlGF 208 
(<5
th
 centile) which is comparable to  PlGF test performance for pre-eclampsia in women with no 209 
underlying disease. This observation, being confirmed in a second cohort, provides  promising 210 
evidence for potential use in the clinical setting but requires further validation.  Identification of 211 
superimposed pre-eclampsia  in women with CKD and/or CHT is substantially more challenging than 212 
detecting pre-eclampsia, as worsening hypertension and proteinuria, the conventional diagnostic 213 
parameters, are difficult to interpret when already present in early pregnancy. Furthermore, only 15 214 
out of 173 women (8.7%) with superimposed pre-eclampsia had additional abnormal laboratory 215 
parameters other than serum creatinine. Over a quarter of all women with CKD and/or CHT required 216 
antenatal admission without delivery to investigate for superimposed pre-eclampsia thus confirming 217 
the need for an accurate test. Quantification of PlGF concentrations at time of suspected 218 
superimposed pre-eclampsia in women with CKD and/or CHT may be a useful adjunctive tool to aid 219 
diagnostic uncertainty. 220 
To our knowledge, this study includes the largest reported number of women with CKD and/or CHT 221 
in whom longitudinal and diagnostic analyses of potential biomarkers for superimposed pre-222 
eclampsia have been assessed. Direct comparison of markers with healthy controls and women with 223 
pre-eclampsia without pre-existing conditions enabled assessment of the influence of pre-existing 224 
disease. We found that PlGF and sFlt-1 concentrations in women with CKD and/or CHT follow the 225 
same gestational trajectories as women without pre-existing disease,
16, 17
 supporting a substantial 226 
placental contribution to the development of superimposed pre-eclampsia whereas the association 227 
between maternal cardiac or renal function quantified by BNP, NGAL and relaxin and the onset of 228 
superimposed pre-eclampsia was not of diagnostic potential.  229 
Diagnostic criteria for superimposed pre-eclampsia as written both in guidelines and reported in 230 
pregnancy studies in CKD and/or CHT are ambiguous.
18, 19
 A strength of our study was the use of 231 
robust thresholds for diagnosis. Changes in blood pressure and proteinuria in normal and CKD 232 
pregnancies are well recognised, and therefore the use of arbitrary thresholds of hypertension and 233 
proteinuria is recognised as potentially problematic, and the thresholds chosen are likely to be 234 
imperfect, particularly as some women may have been delivered prior to the development of 235 
parameters of sufficient severity to reach criteria.  However, in the absence of gestational reference 236 
ranges that accurately reflect anticipated fold changes in blood pressure and proteinuria for women 237 
with CKD and/or CHT this method was chosen for confirmation of superimposed pre-eclampsia, as 238 
reflected in the international definitions. Only three of 161 women with CKD and/or CHT with false 239 
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positive results had clinical courses which were uncomplicated. Importantly, the findings of our 240 
study suggest that PlGF concentrations might be used to define superimposed pre-eclampsia in the 241 
future, thus reducing the need for interpretation of ambiguous clinical parameters. 242 
PlGF in the urine of pregnant women mirrors the plasma concentration
20
 but accumulation of 243 
plasma PlGF in women with reduced renal function could confound interpretation of plasma PlGF. 244 
However, the absence of a correlation between PlGF and serum creatinine renders this unlikely, 245 
although as the number of women with severe CKD was few, this requires further assessment. 246 
Two studies which included small numbers of women with chronic glomerulonephritis (n=15 and 247 
n=35) have suggested previously that PlGF and sFlt-1 may be useful markers for superimposed pre-248 
eclampsia
21, 22
 but a strength of the present, much larger study, is the demonstration of usefulness of 249 
PlGF across a spectrum of CKD aetiologies. Others report that PlGF and sFlt-1 concentrations 250 
discriminated between 34 women with pre-eclampsia (without pre-existing risk factors) and 23 251 
women with CKD without superimposed pre-eclampsia but, unlike the present study women with 252 
superimposed pre-eclampsia were not investigated.
23
 Longitudinal studies, confined to women with 253 
CHT, also report low PlGF and high sFlt-1 concentrations prior to onset and time of diagnosis of 254 
superimposed pre-eclampsia
24,25, 26
 but findings have not been validated in a second cohort as 255 
reported here. Only one study of 313 women with CHT found no differences in PlGF in women with 256 
and without superimposed pre-eclampsia,
27
 despite the cohort having a similar demographic profile 257 
and timing of delivery as the present study; the reasons for these discrepant results are unclear.  258 
In our study one in five (20.4%) women with CKD without superimposed pre-eclampsia was 259 
delivered for other renal related indications including the presence of stable CKD. If confirmed by 260 
further validation, high PlGF concentrations may reduce clinician anxiety and therefore the incidence 261 
of unnecessary admission and preterm iatrogenic delivery due to uncertainty over the clinical 262 
significance of gestational change.  However, a limitation of this study is the number of women with 263 
advanced disease and further study of PlGF in this population is needed. Markers of cardiac and 264 
renal function were not predictive or diagnostic of superimposed pre-eclampsia. Further 265 
haemodynamic assessments in women with CKD and/or CHT are needed to determine the 266 
contribution of pre-existing cardiac and vascular disease to the development of superimposed pre-267 
eclampsia.  In contrast with another report of high specificity of Doppler studies in pregnant women 268 
with CKD,
28
 predictive performance of artery Doppler for prediction of superimposed pre-eclampsia 269 
was poor but may have been limited by non-standardised methods of measurements, frequency and 270 
number of scans performed.   271 
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Conclusions 272 
The findings of this study support the role of PlGF as a diagnostic test for superimposed pre-273 
eclampsia requiring delivery within 14 days for women with CKD and/or CHT, and suggest that 274 
impaired placental function rather than pre-existing maternal disease alone is a major contributor to 275 
the development of superimposed pre-eclampsia. Further investigation of the influence of pre-276 
existing maternal disease on the process of early placentation is required.  277 
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Methods 278 
Longitudinal cohort 279 
Women were prospectively enrolled from two London Academic Health Science Centres (Imperial 280 
College and King’s Health Partners) between June 2009 and September 2013. Ethical approval was 281 
provided by the National Research Ethics Service (NRES) (11/LO/1776) and the study was performed 282 
in accordance with the guidelines of the Declaration of Helsinki. Demographic information was 283 
recorded following written informed consent. Venous blood samples were taken up to four times 284 
during pregnancy and serum and plasma stored at -80
o
C. Maternal and perinatal outcome data were 285 
obtained by case note review after delivery.  Definitions for study entry, and outcomes are based on 286 
International Society of Study of Hypertension in Pregnancy guidelines
29
 (Supplementary Table 1).  287 
The following women were recruited i) women with CKD and/or CHT who did and did not develop 288 
superimposed pre-eclampsia  ii) healthy controls iii) women with pre-eclampsia at time of disease 289 
(without pre-existing disease) iv) women with superimposed pre-eclampsia at time of disease, if they 290 
had not already been recruited longitudinally. 291 
The most recent serum creatinine prior to pregnancy was recorded, and for women with no 292 
measurement available an approximation of eGFR before pregnancy was made by increasing the 293 
first recorded antenatal creatinine by 25% and calculation of eGFR by Modified Diet in Renal Disease 294 
calculation
30
  an approach previously used by others.
3
 Uterine and umbilical artery Doppler studies 295 
were recorded for women with CKD and/or CKD, and the predictive value for development of 296 
superimposed pre-eclampsia of mean uterine artery Doppler pressure indices >1.4 and bilateral 297 
notches at 20-24
+6
 weeks’ and umbilical artery indices >95
th
 centile at >28 weeks’ gestation and 298 
within 14 days of delivery were analysed.  All data and final diagnoses were entered by one 299 
researcher, confirmed by a second reviewer, and for complex cases, the diagnosis was adjudicated 300 
by a third senior reviewer, all without access to study (biomarker) results.  301 
Acute kidney injury was defined as a 50% increase in serum creatinine within one week.
31
 Pregnancy 302 
associated sub-acute kidney injury was defined as a 50% increase in serum creatinine from the 303 
lowest recorded value. Birth-weight was assessed by customised birthweight percentile (gestation 304 
related Optimal Weight),
32
 and small for gestational age (SGA) reported as <3
rd
 and <5
th
 centile. 305 
Validation cohort 306 
Women requiring assessment for suspected pre-eclampsia were enrolled in a longitudinal cohort 307 
study approved by NRES (Ref 10/H0701/117), between January 2011 and February 2012 from seven 308 
consultant-led units in the UK and Ireland, and women with CKD and/or CHT or no pre-existing 309 
disease selected. Details have been described previously.
15
  All samples were taken at time of 310 
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suspected disease in order to assess the diagnostic performance of the test at time of presentation 311 
and were categorised according to outcome at delivery. 312 
Assay analyses 313 
Plasma samples were tested without awareness of clinical outcomes, using the Triage PlGF Tests and 314 
CardioRenal (BNP, NGAL) Test (Alere, San Diego CA) according to the manufacturer’s instructions. 315 
The assays use fluorescently labelled recombinant murine monoclonal antibodies (PlGF, BNP) or 316 
recombinant monoclonal antibodies (NGAL), detecting the biomarkers specifically and quantitatively 317 
within certain ranges (PlGF 12-3000 pg/ml; BNP 5-5000 pg/ml; NGAL 15-1300 pg/ml). The total 318 
precision (coefficient of variation) on plasma controls for PlGF at concentrations of 85 and 1300 319 
pg/ml is 12.8% and 13.2% respectively; for BNP at concentrations of 78 and 3450 pg/ml is 9.2% and 320 
13.9% respectively; for NGAL at concentrations of 98 and 1280 ng/ml is 12.5% and 13.5% 321 
respectively based on the manufacturer’s package inserts generated before the study.   322 
Serum relaxin was quantified using a specific enzyme-linked immunosorbent assay kit according to 323 
the manufacturer’s protocol (R&D Systems, Inc., Minneapolis, MN, USA), with an  assay range of 324 
7.81-500 pg/ml, sensitivity of 4.57 pg/ml and inter and intra-assay coefficients of variation of 3.8% 325 
and 4.3% respectively.   326 
sflt-1 was quantified with a Luminex sandwich assay (Alere, San Diego CA), using  a mouse-derived 327 
recombinant Fab conjugated to a magnetic bead as the capture, and a biotin-conjugated 328 
recombinant Fab as the assay detection, optimised for use in Luminex xMap technology (Alere, San 329 
Diego). The assay range was 0.006-27.87 pg/ml and coefficient of variation 10%.    330 
Statistical analysis 331 
Normality of distribution was explored using a Q-Q plot, and logarithmic transformations used 332 
where appropriate. Demographic data are presented as medians (interquartile range) (as not 333 
normally distributed) or frequencies (percentages). Mann-Whitney, and Fisher’s exact test were 334 
used to test differences between groups.  T-tests were used to test differences between biomarkers 335 
following logarithmic transformation to a normal distribution. PlGF concentrations greater than 19 336 
weeks were transformed into a PlGF centile 
33
 and z-scores calculated. To avoid multiple testing, 337 
data were corrected for the inclusion of women who had provided several samples throughout the 338 
same pregnancy, using interval regression analysis with random-effect modelling for individual 339 
clustering.
34
 Interval regression also allows samples measured as below (above) the lower (upper) 340 
limit of detection to be treated as being in an appropriate range, rather than replacing them with a 341 
single number.  The last visit for each woman of the longitudinal cohort taken after 20 weeks’ 342 
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gestation was included for analysis of diagnostic performance of the primary outcome 343 
(superimposed pre-eclampsia requiring delivery within 14 days). Test performance was evaluated as 344 
sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios 345 
and receiver operator characteristic (ROC) in both cohorts for PlGF <5
th
 Centile and sFlt-1:PlGF ratio 346 
>85 as described by others.
 12,31
Spearman’s rank correlations were performed on the last sample 347 
taken from each woman in order to prevent confounding by frequent sampling within an individual. 348 
Statistical analysis was performed in the statistical package Stata (Version 13) and IBM Statistical 349 
Package for the Social Sciences (SPSS) (Version 21).  The study is reported in accordance with 350 
STAndards for the Reporting of Diagnostic accuracy studies (STARD) guidelines. 351 
Sample size calculation 352 
With 29 cases and 94 controls in the validation set, an unbiased estimate can be obtained within 353 
15% of the true sensitivity and within 8% of the true specificity using 95% confidence intervals 354 
around values of 80% sensitivity and specificity.  355 
Role of the funding source 356 
This was an investigator-led study; the funder had no role in study design, patient recruitment, data 357 
collection, analysis, interpretation, nor in writing of the manuscript or decision to submit for 358 
publication.  359 
Disclosure 360 
KB, PTS, LL, CNP, CG, PW, LP and LC report no conflicts.  361 
 362 
  363 
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Table 1: Longitudinal cohort: Characteristics at First Antenatal Visit and Enrolment  1 
Characteristic 
Healthy 
controls 
(N=79) 
Pre-eclampsia 
(N=32) 
CKD and/or CHT 
without 
superimposed 
pre-eclampsia 
(N=125) 
CKD and/or CHT 
with 
superimposed 
pre-eclampsia 
(N=40) 
Age at booking (years) 
Median (IQR) 
32.0 
(28.0, 36.0) 
29.0 
(26.0, 35.5) 
33.0  
(29.0, 37.0) 
33.5  
(28.2, 37.0) 
BMI (kg/m
2
) 
Median (IQR) 
22.4* 
(20.6, 24.9) 
28.6*  
(24.2, 32.3) 
26.3  
(22.8, 31.5) 
27.1  
(23.8, 32.3) 
Ethnicity     
White 54 (68.4%) 14 (43.8%) 58 (46.4%) 15 (37.5%) 
Black 14 (17.7%)
$
 12 (37.5%)
$
 43 (34.4%) 20 (50.0%) 
Asian 5 (6.3%) 2 (6.3%) 13 (10.4%) 2 (5.0%) 
Other 6 (7.6%) 4 (12.5%) 11 (8.8%) 3 (7.5%) 
Assisted conception 1 (1.2%) 2 (6.3%) 5 (4.0%) 2 (5.0%) 
Nulliparous 49 (62.0%) 24 (75%) 63 (50.4%) 16 (40.0%) 
Previous Fetal Loss     
<12 weeks (≥1) 17 (21.5%) 10 (31.3%) 27 (21.6%)# 16 (40%)# 
12-24 weeks (≥1) 2 (2.5%) 2 (6.2%) 12 (9.6%) 4 (10.0%) 
>24 weeks (≥1) 0 0 6 (4.8%) 6 (15%) 
First antenatal SBP 
Median (IQR)  
102 (100, 110) 112 (109, 123)* 120 (110, 130) ## 124 (115, 137) ## 
First antenatal DBP  
Median (IQR) 
63 (60, 70) 72 (66, 80)* 78 (70, 87)
 ##
 80 (71, 94)
 ##
 
Proteinuria at booking 0 0 
N=122 
32 (26.2%) 
N=40 
7 (17.5%) 
Smoking      
Never 73 (92.4%) 26 (81.3%) 115 (92.0%) 35 (87.5%) 
Current smoker 2 (2.5%) 1 (3.1%) 2 (1.6%) 2 (5.0%) 
Stopped pre/during 
pregnancy 
4 (5.1%) 5 (15.6%) 8 (6.4%) 3 (7.5%) 
Type 1 DM 0 1 (3.1%) 2 (1.6%) SPK 2 (5.0%) SPK 
Type 2 DM 0 1 (3.1%) 2 (1.6%) 1 (2.5%) 
Aspirin Use 1 (1.3%)* 7 (21.9%)* 105 (84.0%) 31 (77.5%) 
Aspirin started before 12 
weeks’ gestation 
1 (100%) 3 (50.0%) 72 (69.9%) 18 (62.1%) 
Median (IQR) gestation 
of start of aspirin  
- 14.5 (3.0, 27.5) 11 (4.0, 13.0) 12 (1.5, 14.5) 
CKD: Chronic Kidney Disease; CHT: Chronic Hypertension; DM: Diabetes mellitus; SPK: Simultaneous 2 
pancreas kidney transplant 3 
Ethnicity – all comparisons with white ethnicity 4 
Healthy controls v pre-eclampsia - *P<0.001; **P=0.008; 
$
P=0.012 5 
CKD and/or CHT without superimposed pre-eclampsia v superimposed pre-eclampsia – #P=0.03; ##P=0.044 6 
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Table 1: Longitudinal cohort: maternal outcomes in women with pre-eclampsia, healthy controls, chronic 1 
hypertension and/or chronic kidney disease with and without superimposed pre-eclampsia. 2 
 3 
Outcome Healthy 
controls 
(N=79) 
Pre-eclampsia 
(N=32) 
CKD and/or CHT 
without 
superimposed 
pre-eclampsia 
(N=125) 
CKD and/or CHT 
with 
superimposed 
pre-eclampsia 
(N=40) 
Onset of labour     
Spontaneous onset 72 (91.1%) 1 (3.1%) 46 (36.8%) 0 
Induction of labour 4 (5.1%)* 27 (84.4%)* 52 (41.6%)* 23 (57.5%)* 
No labour 3 (3.8%)* 4 (12.5%)* 27 (21.6%)* 17 (42.5%)* 
Mode of delivery     
Unassisted vaginal  59 (74.7%) 5 (15.6%) 51 (40.8%) 3 (7.5%) 
Elective Caesarean section 3 (3.8%)** 4 (12.5%)** 27 (21.6%)* 17 (42.5%)* 
Emergency Caesarean 
section 
5 (6.3%)* 19 (59.4%)* 27 (21.6%)* 19 (47.5%)* 
Assisted vaginal  16 (20.5%) 4 (12.5%) 20 (16.0%) 1 (2.5%) 
Details of preeclampsia     
Severe hypertension 
(SBP>160/ DBP>110 mmHg) 
0 19 (61.3%) 15 (12.6%)* 34 (85.0%)* 
Highest SBP 
Median (IQR) 
- 165 (155, 178) 135 (125, 150) * 170 (160, 179) * 
Highest DBP 
Median (IQR) 
- 100 (93, 107) 90 (80, 98.8) * 103.5 (98.5, 113)* 
Highest 24 hr urine 
collection protein (g/24hrs) 
Median (IQR) 
 0.9 (0.37, 2.01) 0.39 (0.28, 0.71)
$$
 0.79 (0.61, 1.55)
$$
 
Highest pregnancy urine 
protein:creatinine ratio  
Median (IQR) 
 59 (29.8, 139) 60 (34, 180)# 79 (51.7, 113.7)# 
Doubling of Proteinuria 0 - 42 (33.9%)* 27 (67.5%)* 
Alanine aminotransferase 
≥70 iu/L 
- 1 (3.1%) 4 (3.2%)$ 6 (15.4%)$ 
Platelet count <100 x10
9
/l - 1 (3.1%) 2 (1.6%) 2 (5.1%) 
Required intravenous 
antihypertensive drugs 
0 8 (25.0%) 0* 7 (17.5%)* 
Required intravenous 
Magnesium Sulfate 
0 4 (12.5%) 0* 10 (25.0%)* 
Additional antihypertensive 
within 4 weeks of delivery 
- - 11 (9.2%)* 32 (82.1%)* 
Admission details     
One or more other 
antenatal admission 
3 (3.8%)*** 5 (15.6%)*** 37 (31.6%) 11 (27.5%) 
Maternal peripartum 2 (1, 4)* 14 (9.7, 22)* 3 (2, 6) * 14 (6, 28) * 
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length of stay 
Median (IQR) 
SBP on discharge 
Median (IQR) 
115 (106, 121)* 135 (127, 146)* 130 (120, 139)
##
 135 (125, 142)
##
 
DBP on discharge Median 
(IQR) 
71 (66, 77)* 85 (78, 91)* 83 (73, 88) 83 (78, 88) 
 4 
Comparison a) between healthy control women and pre-eclampsia b) between women with CKD and/or CHT 5 
with and without superimposed pre-eclampsia 6 
*P<0.0001; **P=0.0038; ***P=0.043; $P=0.014; $$ P=0.012; #P=0.002; ## P=0.028 7 
Labour onset: Comparison made with spontaneous labour 8 
Mode of delivery: Comparison made with vaginal delivery 9 
SBP: Systolic Blood pressure; DBP: Diastolic Blood Pressure; IV: Intravenous 10 
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Table 1: Longitudinal cohort: Women with chronic kidney disease or chronic hypertension developing acute 1 
kidney injury and pregnancy associated sub-acute kidney injury and, and postpartum renal function 2 
 3 
 
CHT 
N=44 
CKD Stage 1 
N=57 
CKD Stage 2 
N=30 
CKD Stage 3 
N=27 
CKD Stage 4 
N=6 
≥2+ Proteinuria at booking 0 21 (38.2%) 4 (12.9%) 11 (40.7%) 3 (50.0%) 
Acute kidney injury 0 0 1 (3.3%) 1 (3.7%) 0 
Pregnancy associated sub-
acute kidney injury 
10 (22.7%) 10 (17.5%) 8 (26.7%) 10 (37.0%) 1 (16.7%) 
6 weeks postpartum - N=17 N=9 N=15 N=3 
Median (IQR) decline in GFR 
mls/min/1.73m
2
 
- 12 (-7, 18) 7 (-0.5, 13) 6 (0, 9) 3 (0, 11) 
≥25% reduction in GFR      
All women - 2 (11.8%) 0 3 (20.0%) 1 (33.3%) 
Women with SPE - 0 0 1 (33.3%) 1 (100%) 
      
6 months postpartum  N=26 N=13 N=17 N=3 
Median (IQR) decline in GFR 
mls/min/1.73m
2
 
- 2 (-7.5, 22.5) 10 (-2.5, 13) 7 (0, 14.0) 6 (0, 13) 
≥25% reduction in GFR      
All women - 2 (7.7%) 2 (15.4%) 4 (23.5%) 2 (66.7%) 
Women with SPE - 0 0 3 (75.0%) 1 (50.0%) 
CKD: Chronic kidney disease; CHT: Chronic hypertension; SPE: Superimposed pre-eclampsia 4 
Pregnancy associated subacute kidney injury: >50% rise in Creatinine during pregnancy 5 
Acute kidney injury: >50% rise in Creatinine during pregnancy within one week 6 
GFR: Glomerular filtration rate 7 
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Table 1: Longitudinal cohort: Neonatal outcomes for women with pre-eclampsia, healthy controls and 1 
women with CKD and/or CHT with and without superimposed pre-eclampsia 2 
CKD: Chronic kidney disease; CHT: Chronic hypertension; NICU: Neonatal intensive care unit; SCBU: Special 3 
care baby unit 4 
For analyses of neonatal outcomes other than intrauterine death, infants with intrauterine death were 5 
excluded  6 
Comparisons are between a) healthy control women and pre-eclampsia b) women with CKD and/or CHT with 7 
and without superimposed pre-eclampsia 8 
*P<0.0001; **P=0.0004; 
$
P=0.0018; 
$$
P=0.035; 
#
P=0.018 9 
 Healthy Controls 
(N=79) 
Pre-eclampsia 
(N=31) 
CKD and/or CHT 
without 
superimposed 
pre-eclampsia 
(N=124) 
CKD and/or CHT 
with 
superimposed 
pre-eclampsia 
(N=39) 
Gestation at delivery 
(weeks) Median (IQR) 
40.1 
(39.4, 41.0)* 
37.4 
(34.6, 38.3)* 
38.4 
(37.4, 39.6)* 
35.6 
(33.3, 38.4)* 
Delivery <34 weeks  0** 6 (19.4%)** 7 (5.6%)* 14 (35.9%)* 
Delivery <37 weeks  3 (3.8%)* 13 (41.9%)* 22 (17.7%)* 24 (61.5%)* 
Intrauterine Death  0 1 (3.1%) 1 (0.8%) 1 (2.5%) 
Apgar <7 at 1 min    3 (3.8%)* 11 (36.7%)* 6 (5.0%)$ 9 (23.7%)$ 
Apgar <7 at 5 min    1 (1.3%) 1 (3.3%) 0 2 (5.3%) 
Birth weight (g ) Median 
(IQR) 
3460 
(3160, 3760)* 
2400 
(1670, 3230)* 
3010 
(2552, 3245)* 
2300 
(1580, 2775)* 
Birth weight centile 
Median (IQR) 
49 (29, 69)* 14 (0, 29)* 28.5 (9.2, 56.7)* 13 (1, 44)* 
Small for Gestational Age 
< 3rd Centile  
0* 10 (31.3%)* 18 (14.4%)
$$
 12 (30.0%)
$$
 
Small for Gestational Age 
< 5
th
 Centile  
4 (5.1%)* 12 (38.7%)* 23 (18.5%)
#
 15 (38.5%)
#
 
Baby transferred to NICU 
or SCBU  
2 (2.6%)* 16 (51.6%)* 11 (8.9%)* 15 (38.5%)* 
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Table 5: Longitudinal cohort: Test performance statistics for low PlGF as a prognostic indicator at time of 1 
sampling for subsequent delivery within 14 days for superimposed pre-eclampsia at 20
+0
-36
+6
 weeks and 2 
20
+0
-40
+6
 weeks in women with chronic kidney disease and/or chronic hypertension 3 
 
PlGF <5th Centile 
for gestation 
PlGF <12 pg/ml PlGF <100 pg/ml 
20
+0
-36
+6
 weeks    
Sensitivity % (95% CI) 
n/N  
75.0 (42.8-94.5) 
9/12 
50.0 (21.1-78.9) 
6/12 
75.0 (42.8-94.5) 
9/12 
Specificity % (95% CI) 
n/N 
77.5 (68.6-84.9) 
86/111 
95.5 (89.8-98.5) 
106/111 
73.9 (64.8-81.7) 
82/111 
Positive Predictive Value % (95% CI) 
n/N 
26.47 (12.9-44.4) 
9/35 
54.5 (23.4-83.2) 
6/11  
23.7 (11.4-40.2) 
9/38  
Negative Predictive Value  (95% CI) 
n/N 
96.6 (90.5-99.3) 
86/89 
94.6 (88.7-98.0) 
106/112  
96.5 (90.0-99.3) 
82/85 
Positive likelihood ratio (95% CI) 3.33 (2.17-5.36) 11.10 (3.98-30.99) 2.87 (1.83-4.51) 
Negative likelihood ratio (95% CI) 0.32 (0.12-0.86) 0.52 (0.30-0.92) 0.34 (0.13-0.91) 
ROC (SE) 0.85 (0.06) - - 
    
20+0-40+6 weeks     
Sensitivity % (95% CI) 
n/N  
68.7 (41.3-89.0) 
11/16 
43.7 (19.7-70.1) 
7/16 
81.2 (54.3-95.9) 
13/16 
Specificity % (95% CI) 
n/N 
81.06 (73.3-87.3) 
107/132 
96.2 (91.4-98.8) 
127/132 
73.5 (65.1-80.8) 
97/132 
Positive Predictive Value % (95% CI) 
n/N 
30.6 (16.3-48.1) 
11/36 
58.3 (27.7-84.8) 
7/12  
27.1 (15.3-41.8) 
13/48 
Negative Predictive Value % (95% 
CI) 
n/N 
95.5 (89.9-98.5) 
107/112 
93.4 (87.8-96.9) 
127/136  
97.0 (91.5-99.4) 
97/100 
Positive likelihood ratio (95 CI) 3.63 (2.24-5.89) 11.55 (4.15-32.15) 3.06 (2.12-4.43) 
Negative likelihood ratio (95 CI) 0.39 (0.19-0.80) 0.58 (0.38-0.90) 0.26 (0.09-0.71) 
ROC (SE) 0.83 (0.08) - - 
CKD: Chronic kidney disease; CHT: Chronic hypertension  4 
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Table 6: Validation cohort: test performance statistics for PlGF <5th centile for gestation as a prognostic 1 
indicators at time of sampling for subsequent delivery within 14 days for pre-eclampsia or superimposed 2 
pre-eclampsia in women with chronic hypertension, chronic kidney disease or no pre-existing disease (20
+0
-3 
36
+6
 weeks and 20
+0
-40
+6
). 4 
 
No pre-existing 
Disease 
CHT or CKD CHT CKD 
20
+0
-36
+6
 weeks     
Sensitivity % (95% CI) 
n/N  
87.4 (79.4-93.1) 
90/103 
78.9 (54.4-93.9) 
15/19 
90.9 (58.7-99.8) 
10/11 
62.5 (24.5-91.5) 
5/8 
Specificity % (95% CI) 
n/N 
54.8 (47.4-62.1) 
102/186 
72.0 (60.4-81.8) 
54/74 
71.2 (57.9-82.2) 
42/59 
75.0 (47.6-92.7) 
12/15 
Positive Predictive Value 
% (95% CI) 
 n/N 
 
51.7 (44.0-59.4) 
90/174 
 
41.7 (25.5-59.2) 
15/36 
 
37.0 (19.4-57.6) 
10/27 
 
55.6 (21.2-86.3) 
5/9 
Negative Predictive Value 
% (95% CI) 
n/N 
 
88.7 (81.4-93.8) 
102/115 
 
93.1 (83.3-98.1) 
54/59 
 
97.7 (87.7-99.9) 
42/43 
 
80.0 (51.9-95.7) 
12/16 
Positive likelihood ratio 
(95% CI) 
1.93 (1.62-2.30) 2.82 (1.83-4.34) 3.16 (2.03-4.91) 2.50 (0.92-6.82) 
Negative likelihood ratio 
(95% CI) 
0.23 (0.14-0.39) 0.29 (0.12-0.71) 0.13 (0.02-0.83) 0.50 (0.20-1.28) 
ROC (SE) 0.84 (0.02) 0.82 (0.06) 0.86 (0.05) 0.79 (0.12) 
     
20
+0
-40
+6
 weeks     
Sensitivity % (95% CI) 
n/N  
74.4 (67.3-80.7) 
131/176 
75.0 (55.1-89.3) 
21/28 
83.3 (58.6-96.4) 
15/18 
60.0 (26.2-87.8) 
6/10 
Specificity % (95% CI) 
n/N 
60.7(54.7-66.5) 
170/280 
75.8 (65.9-84.0) 
72/95 
75.0 (63.7-84.2) 
57/76 
78.9 (54.4-93.9) 
15/19 
Positive Predictive Value 
% (95% CI) 
n/N 
 
54.4 (47.8-60.8) 
131/241 
 
47.7 (32.5 63.3) 
21/44 
 
44.1 (27.2-62.1) 
15/34 
 
60.0 (26.2-87.8) 
6/10 
Negative Predictive Value 
% (95% CI) 
n/N 
 
79.1 (73.0-84.3) 
170/215 
 
91.1 (82.6-96.4) 
72/79 
 
95.0 (86.1-99.0) 
57/60 
 
78.9 (54.4-93.9) 
15/19 
Positive likelihood ratio 
(95% CI) 
1.89 (1.60-2.24) 3.10 (2.05-4.69) 3.33 (2.15-5.18) 2.85 (1.04-7.80) 
Negative likelihood ratio 
(95% CI) 
0.42 (0.32-0.55) 0.33 (0.17-0.63) 0.22 (0.08-0.63) 0.51 (0.23-1.12) 
ROC (SE) 0.79 (0.02) 0.79 (0.05) 0.82 (0.05) 0.75 (0.12) 
CKD: Chronic kidney disease; CHT: Chronic hypertension 5 
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Total enrolled  
n=288 
Outcome data unavailable n=11 
Woman in an intervention randomised 
controlled trial n=1 
Total for analysis  
n=276 
CKD and/or CHT 
n=165 
Time of disease cases with 
pre-eclampsia with no pre-
existing disease 
n=32 
Sample taken between 20+0-36+6 weeks  
n=123 
 
PlGF concentration  
<5th centile 
n=34 
 
PlGF Concentration ≥5th Centile 
n=89 
SPE 
N=20 
 
No SPE 
n=14* 
 
 
SPE 
n=13 
 
 
No SPE 
n=76 
 
Figure 1a: Longitudinal Cohort and Case-Control Flow Diagram of participants 
*Including  
• 3 samples taken <22 weeks’ gestation 
• 8 women with clinical features of SPE but did not meet study criteria for diagnosis 
• 3 women with uncomplicated outcomes 
 
**Including 
2 women who met study criteria for diagnosis but clinical suspicion was low 
1 woman with catastrophic antiphospholipid syndrome 
 
Delivery ≤14 
days 
n=9 
 
 
Delivery >14 
days 
N=11 
 
 
Delivery ≤14 
days 
n=3** 
 
 
Delivery >14 
days 
N=10 
 
Longitudinal Cohort 
n=244 
Healthy Controls 
n=79 
Cases 
n=32 
Samples used for 
biomarker test 
performance in 
women with CKD 
and/or CHT 
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Figure 1b: Validation Cohort – Flow Diagram of participants 
Total enrolled with suspected 
pre-eclampsia/ superimposed 
pre-eclampsia n=625 
Multi-fetal pregnancies n=29 
Other pre-existing disease (but not 
CKD or CHT) n=17 
Total for analysis n=579 
Sample taken between 20+0-40+6 
weeks  
CKD and/or CHT 
n=123 
Sample taken between 20+0-40+6 
weeks  
No pre-existing disease 
n=456 
 
PlGF concentration <5th centile 
n=44 
 
PlGF Concentration ≥5th Centile 
n=79 
 
SPE 
Delivery ≤ 14 
days 
n=21 
 
 
No SPE 
n=23 
 
 
SPE 
Delivery ≤ 14 
days 
n=7 
 
 
PlGF concentration <5th centile 
n=241 
 
PlGF Concentration ≥5th Centile 
n=215 
 
PE 
Delivery ≤ 14 
days 
n=131 
 
 
No PE 
n=110 
 
 
PE 
Delivery ≤ 14 
days 
n=45 
 
 
No PE 
n=170 
 
 
No SPE 
n=72 
 
SPE: Superimposed pre-eclampsia; PE: Pre-eclampsia; PlGF: Placental Growth Factor; CKD: Chronic kidney 
disease; CHT: Chronic Hypertension 
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Figure 2: Maternal plasma placental growth factor concentrations in healthy controls,  women with 
CHT and/or CKD with and without superimposed pre-eclampsia in a longitudinal cohort and in 
women with time of disease pre-eclampsia, according to gestation in weeks 
Mean plasma PlGF concentrations according to gestation in weeks. Bars represent standard errors. 
Samples were taken from women with SPE before and at time of disease onset. Samples from women 
with pre-eclampsia were taken after diagnosis.   P values are given are for the comparisons between 
overall PlGF concentration women after logarithmic transformation  in samples from women with CHT 
and/or CKD with and without superimposed pre-eclampsia (*), and healthy controls compared with 
women with pre-eclampsia without pre-existing disease (**).  
 
CKD: Chronic kidney disease; CHT: Chronic hypertension 
Healthy Control 
CHT and or/ CKD 
Pre-eclampsia 
Superimposed pre-
eclampsia 
Gestation (eks) tation we  
10-12 13-16 17-20 21-24 25-28 29-32 33-35 37-42 
1 
10 
100 
1000 
12 
P
la
c
e
n
ta
l 
G
ro
w
th
 F
a
c
to
r 
(p
g
/m
l)
 l
o
g
 s
c
a
le
 
 Healthy Control  Pre-eclampsia (time of disease) 
 CHT and/or CKD  Superimposed pre-eclampsia 
* 
* 
** 
** 
*  P<0.001 
**P<0.001 
Number of 
Samples 
Healthy 
Controls 
41 12 27 8 7 15 21 5 
CHT/CKD  11 28 37 34 36 41 37 36 
Superimposed 
Pre-eclampsia 
1 4 6 9 9 13 12 4 
Pre-eclampsia -   - -  2 2 5 14 9 
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Web extra material 
Supplementary Table 1: Definitions for study entry 
Definition Criteria 
Healthy control women • No risk factors for pre-eclampsia 
• No history of pre-eclampsia, hypertension, diabetes, renal disease, connective tissue disease or 
anti-phospholipid antibody syndrome  
• Systolic blood pressure <140mmHg  
• Diastolic blood pressure <90mmHg  
• No protein on dipstick analysis of midstream urine 
• Not in labour 
Gestational Hypertension • Previously normotensive 
• Two recordings of systolic blood pressure ≥140mmHg or diastolic blood pressure ≥ 90mmHg 
greater than 4 hours apart  
• After 20 weeks’ gestation  
• Not in labour 
Pre-eclampsia • Gestational Hypertension 
AND 
• Proteinuria of >300mg protein over 24 hours, (or protein:creatinine ratio of >30mg/mmol); 
Superimposed pre-eclampsia 
Hypertension already present 
•  New onset of proteinuria >300mg protein over 24 hours, (or protein:creatinine ratio of  
>30mg/mmol); 
OR 
Additional features – severe persistent right upper quadrant pain or epigastric pain unresponsive to 
mediation or alanine transaminase < 71U/l or platelet count <100,000/µl or pulmonary oedema or new 
onset cerebral or visual disturbance 
Superimposed pre-eclampsia 
Proteinuria already present 
• Two recordings of systolic blood pressure ≥140mmHg or diastolic blood pressure ≥ 90mmHg 
greater than 4 hours apart  
OR 
• Additional features as listed above 
Superimposed pre-eclampsia 
Hypertension and proteinuria 
already present 
• Development of severe hypertension (Systolic blood pressure ≥160mmHg or diastolic blood 
pressure ≥110mmHg)  
AND 
• Greater than two fold increase in proteinuria above 300mg protein over 24 hours, (or 
protein:creatinine ratio of >30 mg/mmol); 
OR 
Additional features as listed above 
Primary Hypertension • Maternal diastolic blood pressure of 90mmHg or more before 20 weeks’ gestation in the current 
pregnancy 
OR 
• Taking antihypertensive agents before 20 weeks’ gestation  
OR 
• Taking antihypertensives prior to pregnancy  
 
• Secondary causes of hypertension excluded 
Chronic Hypertension • Primary or secondary causes of hypertension 
Chronic Kidney Disease • According to Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines pre-
pregnancy{Guidelines,  #50302}  
OR 
• Persistent proteinuria (>1+ or 30mg/mmol (protein creatinine ratio) before 20 weeks’ gestation  
OR  
• Any recorded serum creatinine >70µmol before 20 weeks’ gestation without risk factors for acute 
kidney injury; 
Exclusion • Women < 18 years old or >50 years old 
• Inability or unwillingness to give informed consent 
• Known HIV, Hepatitis B or C positive 
• Multi-fetal Pregnancy 
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Supplementary Table 2: Longitudinal cohort: disease aetiology in women with chronic hypertension and/or 
chronic kidney disease according to development of superimposed pre-eclampsia 
Characteristic 
CHT and/or CKD without 
superimposed pre-eclampsia 
(N=125) 
 
CHT and/or CKD with superimposed 
pre-eclampsia 
(N=40) 
Primary hypertension 27 (21.6%)* 17 (42.5%)* 
Chronic kidney disease only 53 (42.4%)** 8 (20.0%)** 
Chronic kidney disease with hypertension 45 (36.0%) 15 (37.5%) 
 
  
Definition of CHT N=72 N=32 
Pre pregnancy anti-hypertensives 58 (80.5%) 24 (75.0%) 
Antihypertensive <20 weeks 54 (75.0%) 22 (68.8%) 
DBP >90 mmHg <20 weeks 29 (40.3%) 15 (46.9%) 
 
  
CKD Stage N=98 N=23 
1 46 (47%) 10 (43.5%) 
2 27 (28%) 4 (17.4%) 
3 21 (21%) 6 (26.1%) 
4 3 (3.1%) 3 (13.0%) 
5 1 (1.0%) - 
≥2+ Proteinuria at booking N=122 32 (26.2%) 
N=40 
7 (17.5%) 
 
  
CKD Diagnosed during pregnancy N=98 14 (14.3%) 
N=23 
5 (21.7%) 
Biopsy proven CKD N=97 45 (46.4%) 
N=23 
9 (39.1%) 
 
  
Cause of CKD   
Adult Polycystic kidney disease 4 (4.1%) 2 (8.7%) 
Reflux 8 (8.2%) 2 (8.7%) 
Lupus 22 (22.4%) 5 (21.7%) 
Immunoglobulin A nephropathy 10 (10.2%) 1 (4.3%) 
Minimal Change 3 (3.1%) 0 
Focal Segmental Glomerulosclerosis 7 (7.1%) 1 (4.3%) 
Vasculitits 1 (1.0%) 0 
Interstitial 4 (4.1%) 1 (4.3%) 
Transplant 8 (8.2%) 1 (4.3%) 
Simultaneous Pancreas Kidney Transplant 2 (2.0%) 2 (8.7%) 
Hypertensive Nephropathy 3 (3.1%) 0 
Diabetic Nephropathy 1 (1.0%) 1 (4.3%) 
Multiple Calculi with impaired function 3 (3.1%) 0 
Single Kidney 2 (2.0%) 1 (4.3%) 
End Stage 1 (1.0%) 0 
Undiagnosed 19 (19.4%) 6 (26.1%) 
 
*p=0.013; ** p=0,0014 
CHT: Chronic Hypertension; CKD: Chronic Kidney Disease 
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Supplementary Table 3: Longitudinal cohort: demographics of women with primary hypertension and chronic 
kidney disease according to stage 
 
CHT 
N=44 
CKD Stage 1 
N=56 
CKD Stage  2 
N=31 
CKD Stage 3 
N=27 
CKD Stage 4 or 5 
N=7 
Age Category 
(years)   
 
  
<20 0 0  1 (3.2%) 0 0 
20-29 11 (25%) 24 (42.9%) 8 (25.8%) 6 (18.5%) 1 (14.3%) 
30-39 22 (50%) 31 (55.4%) 18 (58.1%) 18 (66.7%) 6 (85.7%) 
≥40 11 (25%) 1 (1.8%) 4 (12.9%) 4 (14.8%) 0 
      
BMI Category 
(kg/m2)   
 
  
<20 0 8 (14/3%) 2 (6.5%) 2 (7.4%) 0 
20-24 10 (22.7%) 20 (35.7%) 12 (38.7%) 13 (48.1%) 3 (42.9%) 
25-29 12 (27.3%) 11 (19.6%) 9 (29.0%) 8 (29.6%) 3 (42.9%) 
30-34 11 (25.0%) 10 (17.9%) 5 (16.1%) 2 (7.4%) 1 (14.3%) 
35-39 8 (18.2%) 4 (7.1%) 2 (6.5%) 2 (7.4%) 0 
≥40 3 (6.8%) 3 (5.4%) 1 (3.2%) 0 0 
      
      
Ethnicity      
White 17 (38.6%) 21 (37.5%) 14 (45.2%) 19 (70.4%) 2 (28.6%) 
Black 25 (56.8%)* 21 (37.5%) 9 (29.0%) 4 (14.8%)* 4 (57.1%) 
Asian 1 (2.3%) 6 (10.7%) 6 (19.4%) 2 (7.4%) 0 
Other 1 (2.3%) 8 (14.3%) 2 (7.1%) 2 (7.4%) 1 (14.3%) 
      
Smoking      
Never 39 (88.6%) 51 (91.1%) 29 (93.5%) 24 (88.9%) 7 (100%) 
Stopped before 
pregnancy 1 (2.3%) 
2 (3.5%) 1 (3.2%) 0 0 
Current 4 (9.1%) 3 (5.4%) 1 (3.2%) 3 (11.1%) 0 
      
Nulliparous 16 (36.4%) 31 (55.4%) 16 (51.6%) 14 (51.9%) 2 (28.6%) 
      
One or more 
pregnancy losses   
 
  
≤12 weeks 9 (20.5%) 17 (30.4%) 6 (19.4%) 8 (29.6%) 1 (14.3%) 
13-24 weeks 3 (6.8%) 6 (10.7%) 3 (9.7%) 3 (11.1%) 1 (14.3%) 
≥24 weeks 4 (9.1%) 5 (8.9%) 2 (6.5%) 1 (3.7%) 0 
      
≥2+ Proteinuria at 
booking 
N=43 
0 
N=55 
21 (38.2%) 
N=31 
4 (12.9%) 
N=27 
11 (40.7%) 
N=6 
3 (50.0%) 
Chronic 
hypertension 44 (100%) 21 (37.5%) 15 (48.4%) 18 (66.7%)** 5 (71.4%) 
      
Assisted 
Conception 0 2 (3.6%) 2 (6.5%) 3 (11.1%) 0 
 
 N=41 N=25 N=23 N=7 
Median Pre-
pregnancy eGFR 
(IQR) 
mls/min/1.73m2 
- 108 (103, 123) 66 (76, 82) 49 (40, 54) 23 (15, 28) 
Median Pre-
pregnancy 
Creatinine µmol/l 
- 61 (55, 66) 89 (80, 95) 
 
116 (108, 141) 266 (201, 384) 
 
CHT: Chronic Hypertension; CKD: Chronic Kidney Disease; eGFR: Estimated glomerular filtration rate 
*Primary hypertension v CKD Stage 1 or 2 p=0.0015 compared with white ethnicity 
** CKD Stage 1 or 2 v Stage 3 p=0.046 
 
  
Page 47 of 57
The International Society of Nephrology (http://www.isn-online.org/site/cms)
Kidney International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Supplementary Table 4: Longitudinal cohort: outcomes according to presence of chronic hypertension or stage 
of chronic kidney disease 
Key outcomes Primary CHT CKD stage 1-2 CKD stage 3 CKD stage 4-5 
Primary CHT 
v Stage 1-2 
P value 
Stage 1-2 
v 3 
P value 
Stage 1-2 
v 4-5 
P value 
Delivery <34 weeks N=43 3 (7.0%)* 
N=86 
9 (10.5%) 
N=28 
4 (14.3%) 
N=7 
3 (42.9%) NS NS 0.043 
Delivery <37 weeks N=43 8 (18.6%) 
N=86 
20 (23.3%) 
N=28 
11 (39.3%) 
N=7 
7 (100.0%) NS NS 0.0001 
Intrauterine Death N=43 1 (2.3%) 
N=87 
1 (1.0%) 
N=28 
0 (0.0%) 
N=7 
0 (0.0%) NS NS NS 
Gestation at 
delivery (weeks) 
Median (IQR) 
39.00 
(37.79-39.57) 
38.12 
(37.12-39.00) 
37.22 
(35.93-38.00) 
34.00 
(33.29-35.50) NS 0.006 0.006 
Birth weight (g ) 
Median (IQR) 
3100 
(2580-3475) 
2939 
(2500-3210) 
2490 
(2128-2849) 
1840 
(1830-2173) NS 0.002 0.002 
Birth weight centile 
Median (IQR) 
25.0 
(7.0-50.0) 
29.0 
(13.0-57.0) 
12.5 
(1.0-40.5) 
4.0 
(3.5-18.5) NS 0.01 0.021 
Small for 
Gestational Age 
< 3rd Centile 
N=43 
9 (20.9%) 
N=86 
10 (11.6%)* 
N=28 
10 (35.7%)* 
N=7 
2 (28.6%) 
 
NS 
 
0.008 
 
NS 
Small for 
Gestational Age 
< 5rd Centile 
N=43 
10 (23.3%) 
N=86 
14 (16.3%) 
N=28 
11 (39.3%) 
N=7 
4 (57.1%) NS 0.017 0.025 
Baby transferred to 
NICU or SCBU 
N=43 
4 (9.3%) 
N=85 
10 (11.8%) 
N=28 
9 (32.1%) 
N=7 
4 (57.1%) NS 0.019 0.009 
 
CHT: Chronic hypertension; CKD: Chronic kidney disease; NICU: Neonatal intensive care unit; SCBU: Special 
care baby unit; NS: Not significant 
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Supplementary Table 5: Longitudinal cohort: predictive value of PlGF concentration <5th centile in women 
with chronic hypertension or chronic kidney disease between women who did and did not develop superimposed 
pre-eclampsia before disease onset according to gestation, excluding women with diagnosed superimposed pre-
eclampsia 
Gestation 21-24+6 weeks 25-28+6 weeks 29-32+6 weeks 33-36+6 weeks 
Sensitivity % (95% CI) 
n/N 
25 (3.2-65.1) 
2/8 
66.7 (22.3-95.7) 
4/6 
42.9 (9.9-81.6) 
3/7 
50.0 (6.8-93.2) 
2/4 
Specificity % (95% CI) 
n/N 
97.1 (84.7-99.9) 
33/34 
97.1 (85.1-99.9) 
34/35 
87.8 (73.8-95.9) 
36/41 
86.1 (70.5-95.3) 
31/36 
Positive Predictive Value % (95% CI) 
 n/N 
66.7 (9.4-99.2) 
2/3 
80.0 (28.4-99.5) 
4/5 
37.5 (8.5-75.5) 
3/8 
28.6 (3.7-71.0) 
2/7 
Negative Predictive Value % (95% CI) 
n/N 
84.6 (69.5-94.1) 
33/39 
94.4 (81.3-99.3) 
34/36 
90.0 (76.3-97.2) 
36/40 
93.9 (79.8-99.3) 
31/33 
Positive likelihood ratio (95% CI) 8.50  
(0.88-82.57) 
23.33 
(3.12-174.65) 
3.51  
(1.07-  11.50) 
3.60  
(1.01-12.86) 
Negative likelihood ratio (95% CI) 0.77 
(0.52-1.16) 
0.34 
(0.11-1.07) 
0.65 
(0.34-1.25) 
0.58 
(0.22-1.56) 
ROC (SE) 0.53 (0.14) 0.78 (0.16) 0.64 (0.13) 0.83 (0.09) 
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Supplementary Table 6: Longitudinal cohort: false positives (PlGF <5th Centile) and false negatives (PlGF≥5th Centile) for women with chronic hypertension or chronic 
kidney disease for samples taken between 20 and 36+6 weeks’ gestation 
Subject CHT or CKD Gestation Sampling 
Gestation 
Delivery 
PlGF 
(pg/ml) 
PlGF 
Centile 
Creatinine 
(µmol/L) 
Birth 
Weight 
(g) 
Birth 
Weight 
Centile 
Severe 
Hypertension 
Doubling of 
Proteinuria 
over threshold 
Details 
False Positives            
Clinical suspicion of superimposed pre-eclampsia but did not meet criteria     
21 
CKD Stage 1 
Lupus nephritis (Unknown 
class) and CHT 
31+6 32+0 56.6 1 66 1950 46 0 1 
Induced day after sample taken for fetal 
growth restriction. Neonatal death at 8 
weeks. 
41 
CKD Stage 1 
CHT and previous calculi 
and hydronephrosis 
32+0 38+6 <12 0 51 2650 8 1 0 Elective section for cerebral aneurysm. Poorly controlled blood pressure. 
66 CKD Stage 2 ANCA vasculitis 34
+3
 37+1 41.6 3 78 2550 13 0 0 
Clinical suspicion of superimposed pre-
eclampsia at 34 weeks’ but expectant 
management until 37 weeks. 
79 CKD Stage 3 Class IV Lupus 28
+0
 30+1 52.6 0 185 1130 1 0 1 Spontaneous preterm labour at 30 weeks 
with fetal growth restriction. 
83 CKD Stage 2 Renal Transplant and CHT 35
+3
 37+2 24 2 109 3120 73 0 1 
Induced for increasing creatinine and 
falling platelets, but did not meet criteria 
for superimposed pre-eclampsia 
160 CHT only 34+4 39+1 40.3 3 53 3040 14 1 0 Induced for reduced fetal growth Transient proteinuria above threshold 
179 CKD Stage 1 Class V lupus 30
+4
 32+5 36.1 0 84 1890 17 0 1 
Induced for reduced fetal growth and 
cardiac defect; clinical suspicion of 
superimposed pre-eclampsia but 
hypertension not over threshold. 
180 CKD Stage 1 Class III and IV lupus 20
+6
 24+1 <12 0 68 280 0 0 0 
Active lupus nephritis 
Intrauterine death of growth restricted fetus 
at 24 weeks 
No clinical suspicion of superimposed pre-eclampsia 
4 CKD Stage 3  Hypertensive Nephropathy 20
+3
 37+6 57.5 3 84 2220 1 1 1 Early sampling 
40 CHT only 30+4 38+2 116 3 45 3350 62 0 0 Spontaneous labour No complications 
196 CKD Stage 1 Minimal Change Disease 34
+2
 40+3 50.3 4 58 2910 7 0 0 Spontaneous labour No complications 
285 CHT only 21+1 35+4 36 0 65 1620 0 0 0 Early sampling 
289 CKD Stage 3 and CHT Unknown cause 20
+5
 38+3 55.3 3 75 2095 0 0 0 Early sampling 
731 CKD Stage 1 Medullary Sponge Kidney 33
+0
 40+2 12.4 0 117 3200 21 0 0 Spontaneous labour No complications 
False Negatives           
170 
CKD Stage 3 
Kidney Pancreas 
Transplant and CHT 
30+4 32+2 2630 98 132 1750 20 1 1 
Recurrent admissions for suspected 
superimposed pre-eclampsia with 
fluctuating creatinine. Elective section for 
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increasing creatinine. 
252 
CKD Stage 1 
Type 1 DM with newly 
diagnosed nephropathy 
33+0 34+1 115 9 46 2650 71 1 1 
Unclear clinical diagnosis as possible 
gestational hypertension and but met 
diagnostic criteria.  Induced for fetal 
decelerations 
263 CHT and antiphospholipid 
syndrome 34
+2
 34+3 187 30 84 2320 25 1 0 Delivery for HELLP syndrome and 
suspected fetal growth restriction 
 
CHT: Chronic hypertension; CKD: Chronic Kidney Disease; PlGF: Placental growth factor; Severe Hypertension: Systolic blood pressure ≥160mmHg or Diastolic blood 
pressure ≥110mmHg; DM: Diabetes Mellitus; HELLP: Haemolysis elevated liver enzymes, low platelets 
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Supplementary Table 7: Predictive value of uterine and umbilical artery Dopplers in women with chronic 
hypertension or chronic kidney disease for superimposed pre-eclampsia  
 
Uterine artery 
Mean PI >1.4 
20-24+6 weeks 
Uterine artery 
bilateral 
notching 
20-24+6 weeks 
Umbilical 
artery PI >95th 
Centile 
All studies>28 
weeks 
Umbilical 
artery PI 
>95th Centile 
<14 days 
before delivery 
Sensitivity % (95% CI) 
n/N 
20.00 
(3.1-55.6) 
2/10 
28.57 
(8.6 -58.1) 
4/14 
7.69 
(1.3 -36.1) 
1/13 
11.11 
(1.8 -48.3) 
1/9 
Specificity % (95% CI) 
n/N 
100.00 
(78.0 -100.0) 
15/15 
92.59 
(75.7 -98.8) 
25/27 
91.84 
(80.3 -97.7) 
45/49 
92.31 
(63.9 -98.7) 
12/13 
Positive Predictive Value % (95% CI) 
 n/N 
100.00 
(19.3 -100.0) 
2/2 
66.67 
(22.7 -94.7) 
4/6 
20.00 
(3.3 -71.2) 
1/5 
50.00 
(8.2 -91.8) 
1/2 
Negative Predictive Value % (95% CI) 
n/N 
65.22 
(42.7 -83.6) 
15/23 
71.43 
(53.7 -85.3) 
25/35 
78.95 
(66.1 -88.6) 
45/57 
60.00 
(36.1 -80.8) 
12/20 
Positive likelihood ratio (95% CI) 
 
3.86 
(0.80-18.54) 
0.94 
(0.11-7.73) 
1.44 
(0.10-20.21) 
Negative likelihood ratio (95% CI) 0.80 
(0.6-1.1) 
0.77 
(0.5-1.1) 
1.01 
(0.8-1.2) 
0.96 
(0.7-1.3) 
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Supplementary Table 8: Validation cohort: characteristics at first antenatal visit and enrolment at time 
suspected pre-eclampsia 
Characteristic No pre-existing Disease N=456 
Chronic Hypertension 
N=94 
Chronic Kidney Disease 
N=29 
Age (years) 
Median (IQR) 
31.2  
(26.5 to 35.3) 
33.5  
(30.7 to 36.6) 
32.7 
(29.2 to 38.2) 
Body Mass Index (kg/m2) 
Median (IQR) 
27.7  
(23.6 to 31.6) 
31.1  
(26.7 to 36.8) 
26.3  
(23.7 to 30.3) 
Systolic blood pressure at first 
antenatal visit (mmHg) 
Median (IQR) 
118.0  
(108.3 to 122.0) 
140.0  
(126.8 to 145.0) 
120.0  
(117.0 to 133.5) 
Diastolic blood pressure at first 
antenatal visit (mmHg) 
Median (IQR) 
70.0  
(64.0 to 78.0) 
88.0  
(80.0 to 92.0) 
75.0  
(70.0 to 83.0) 
Nulliparous 275 (60.3%) 36 (38.3%) 14 (48.2%) 
Ethnicity    
White 313 (68.6%) 59 (62.8%) 21 (72.4%) 
Black 80 (17.5%) 26 (27.7%) 8 (27..6%) 
Asian 36 (7.9%) 5 (5.3%) 0 
Other 27 (5.9%) 4 (4.3%) 0 
Smoking  N=91  
Never 324 (72.3%) 72 (79.1%) 22 (75.9%) 
Ex-smoker 80 (17.9%) 13 (14.3%) 5 (17.2%) 
Current 44 (9.8%) 6 (6.6%) 2 (6.9%) 
Previous Pre-eclampsia N=452 N=93  
<34 weeks’ 24 (5.3%) 16 (17.2%) 3 (10.7%) 
≥34 weeks’ 43 (9.5%) 8 (8.6%) 3 (10.7%) 
Other disease  N=90  
Antiphospholipid Syndrome or 
Systemic Lupus Erythematosus 0 1 (1.1%) 3 (10.3%) 
Pregestational Diabetes Mellitus 0 4 (4.4%) 2 (6.9%) 
Chronic Hypertension 0 94 (100%) 8 (27.6%) 
 
Enrolment/Suspected pre-eclampsia    
Gestation week 
Median (IQR) 
35.9  
(32.5 to 37.9) 
34.1  
(27.9 to 37.0) 
33.4  
(30.6 to 36.6) 
Signs/symptoms of suspected pre-
eclampsia (non-exclusive)    
New onset hypertension 342 (75.0%) 22 (23.4%) 16 (55.1%) 
Worsening of underlying 
hypertension 45 (98.7%) 58 (61.7%) 6 (20.7%) 
New onset dipstick proteinuria 260 (57.0%) 46 (48.9%) 18 (62.1%) 
Persistent epigastric  /right upper 
quadrant pain 27 (5.9%) 6 (22.2%) 2 (6.9%) 
Headaches/Visual Disturbance 157 (34.4%) 30 (31.9%) 8 (27.6%) 
Suspected fetal growth restriction 27 (5.9%) 2 (2.1%) 0 
 
Enrolment Laboratory 
Parameters 
Median (IQR) 
   
Alanine Transaminase (U/L) 
N=403 
14.0  
(11.0 to 20.0) 
N=81 
14.0  
(11.0 to 20.0) 
N=23 
16.0  
(12.0 to 25.0) 
Creatinine (µmol/L) 
N=433 
53.0  
(46.0 to 62.0) 
N=86 
55.0  
(45.0 to 64.0) 
N=26 
70.5  
(50.8 to 118.0) 
Uric acid (µmol/L) 
N=321 
300.0  
(220.0 to 360.0) 
N=64 
264.0  
(220.8 to 329.8) 
N=15 
335.0  
(246.0 to 380.0) 
Platelets (x109 /L) 
N=438 
220.0  
(180.0 to 266.0) 
N=87 
243.0  
(206.0 to 277.0) 
N=27 
242.0  
(187.0 to 269.0) 
Proteinuria N=407 N=80 N=23 
Negative or trace 162 (39.8) 40 (48.8) 4 (17.4) 
1 105 (25.8) 25 (30.5) 7 (30.4) 
≥2 140 (34.4) 17 (20.7) 12 (52.2) 
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Supplementary Table 9: Validation cohort: maternal and neonatal outcomes  
  
 
 
No pre-existing Disease 
N=456 
Chronic Hypertension 
N=94 
Chronic Kidney Disease 
N=29 
Maternal Outcomes    
Pre-eclampsia/ Superimposed pre-eclampsia 253 (55.5%) 44 17 
Final Diagnosis N=253   
Mild pre-eclampsia 82 (32.4%) - - 
Severe pre-eclampsia 110 (43.5%) - - 
Atypical pre-eclampsia 58 (22.9%) - - 
Eclampsia 1 (0.4%) 0 0 
HELLP Syndrome 2 (0.8%) 0 0 
Gestational Hypertension 79 (31.2%) 0 1 (3.4%) 
Isolated Proteinuria 21 (8.3%) 0 4 (13.8%) 
Isolated SGA (<10th Customised birthweight centile) 12 (4.7%) 0 0 
Transient Hypertension 50 (19.8%) 0 2 (6.9%) 
Normal 37 (14.6%) 0 0 
Other 4 (1.6%) 0 1 (3.4%) 
Adverse maternal parameters    
Highest systolic (mmHg) Median (IQR) 143.0 (131.0 to 155.0) 150.0 (140.0 to 160.0) 140.0 (129.0 to 150.5) 
Highest diastolic (mmHg) Median (IQR) 92.0 (84.0 to 100.0) 97.5 (90.0 to 102.0) 83.0 (79.0 to 94.5) 
Severe hypertension (SBP>160) 115 (25.2%) 30 (6.6%) 5 (17.2%) 
Alanine aminotransferase >70 iu/L 28 (6.1%) 5 (5.3%) 2 (6.9%) 
Platelets<50 x109 /l 1 (0.2%) 0 0 
Antihypertensive Use    
1 drug 91 (20.0%) 22 (23.4%) 5 (17.2%) 
2 drugs 38 (8.3%) 23 (24.5%) 5 (17.2%) 
≥ 3 drugs 15 (3.3%) 9 (9.6%) 4 (13.8%) 
Required IV Magnesium Sulphate 7 (1.5%) 1 (1.0%) 1 (3.4%) 
Onset of labour N=454 N=92 N=29 
Spontaneous 103 (22.7%) 12 (13.0%) 4 (13.8%) 
Induction of labour 221 (48.7%)  45 (48.9%) 14 (48.3%) 
Prelabour Caesarean Section 130 (28.6%) 35 (38.0%) 11 (37.9%) 
Mode of delivery N=434 N=93 N=28 
Spontaneous vaginal 171 (39.4%) 35 (37.6%) 7 (25.0%) 
Caesarean 209 (48.2%) 49 (52.7%) 17 (60.7%) 
Assisted vaginal 54 (12.4%) 9 (9.7%) 4 (14.3%) 
Proteinuria    
No proteinuria 175 (38.4%) 42 (44.7%) 7 (24.1%) 
Dipstick Proteinuria 
Present (1+ or greater) 120 (26.3%) 26 (27.7%) 8 (27.6%) 
Protein: Creatinine Ratio > 30mg/mmol 87 (19.1%) 9 (9.6%) 8 (27.6%) 
24 hour urine >300mg 74 (16.2%) 17 (18.1) 6 (20.7%) 
Neonatal Outcomes    
Perinatal Death 6 (1.3%) 2 (2.1%) 1 (3.4%) 
Gestation at delivery (weeks) Median (IQR) 38.4 (36.9 to 39.7) 38.1 (36.2 to 40.0) 37.0 (35.9 to 38.3) 
Preterm <37 weeks’ 118 (25.9%) 32 (34.0%) 13 (44.8%) 
Preterm <34 weeks’ 51 (11.2%) 12 (12.8%) 5 (17.2%) 
Birth Weight (g) Median (IQR) 3053 (2303 to 3438) 3035 (2500 to 3398) 2500 (2260 to 3125) 
SGA (<10th customised birth weight centile) 161 (35.3%) 35 (37.2%) 11 (37.9%) 
SGA (<3rd customised birth weight centile) 112 (24.6%) 18 (19.1%) 6 (20.7%) 
 
HELLP: Haemolysis, elevated liver enzymes and low platelets 
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Supplementary Table 10: Validation cohort: Median and interquartile ranges for low PlGF, sFlt-1 and sFlt-
1:PlGF for women with chronic hypertension, chronic kidney disease and no pre-existing disease at 20+0-33+6 
weeks’, 20+0-36+6 weeks’, and 20+0-40+6 weeks’ gestation 
 
 
 
No pre-existing 
Disease 
Pre-eclampsia 
No pre-existing 
Disease 
No Pre-
eclampsia 
Chronic 
Hypertension 
Pre-eclampsia 
Chronic 
Hypertension 
No Pre-
eclampsia 
Chronic Kidney 
Disease 
Pre-eclampsia 
Chronic Kidney 
Disease 
No Pre-
eclampsia 
20+0-33+6 N=49 N=106 N=5 N=41 N=5 N=10 
PlGF 
pg/ml 
10.0 
(10.0,14.1) 
152.8 
(42.6,362.7) 
10.0 
(10.0,10.0) 
282.2 
(88.9,553.2) 
10.0 
(10.0,24.2) 
207.7 
(87.5,449.4) 
sFlt-1 
pg/ml 
 
5.2 
(3.0,9.6) 
0.9 
(0.6,1.8) 
4.5 
(1.2,5.8) 
0.9 
(0.5,1.8) 
4.3 
(3.0,4.5) 
0.9 
(0.5,2.2) 
sFlt-1 
:PlGF 
 
44.4 
(22.1,95.5) 
0.6 
(0.1,3.8) 
45.3 
(10.0,58.4) 
0.3 
(0.1,2.1) 
30.0 
(25.3,43.0) 
0.4 
(0.1,2.6) 
20+0-36+6 N=103 N=186 N=11 N=59 N=8 N=16 
PlGF 
pg/ml 
 
10.0 
(10.0,24.2) 
97.2 
(26.8,296.9) 
12.9 
(10.0,28.2) 
214.0 
(46.9,414.6) 
21.2 
(10.0,54.3) 
234.9 
(59.7,372.6) 
sFlt-1 
pg/ml 
 
5.4 
(2.9,8.0) 
1.3 
(0.7,3.4) 
4.5 
(1.2,6.1) 
1.1 
(0.5,2.3) 
4.4 
(3.0,5.4) 
0.9 
(0.5,2.8) 
sFlt-1 
:PlGF 
 
33.0 
(16.0,67.5) 
1.3 
(0.3,11.1) 
27.2 
(10.0,58.4) 
0.5 
(0.1,8.0) 
27.7 
(7.1,37.6) 
0.3 
(0.1,5.7) 
20+0-40+6 N=176 N=279 N=18 N=76 N=10 N=19 
PlGF 
pg/ml 
 
14.5 
(10.0,29.0) 
60.0 
(23.2,246.0) 
13.3 
(10.0,28.2) 
116.7 
(34.6,327.7) 
21.2 
(10.0,61.0) 
209.4 
(65.7,295.8) 
sFlt-1 
pg/ml 
 
5.1 
(2.8,7.2) 
1.8 
(0.9,3.9) 
4.0 
(2.3,6.1) 
1.4 
(0.6,2.5) 
3.7 
(2.4,4.9) 
1.1 
(0.5,3.4) 
sFlt-1 
:PlGF 
29.7 
(12.1,56.9) 
3.0 
(0.3,15.1) 
25.1 
(10.0,53.1) 
1.2 
(0.2,8.5) 
21.6 
(6.2,32.3) 
0.4 
(0.1,6.9) 
 
CKD: Chronic kidney disease; CHT: Chronic hypertension; PlGF: Placental Growth Factor; sFlt-1: soluble fms 
like tyrosine kinase receptor-1 
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Supplementary Table 11: Validation cohort: Receiver Operator Curve Areas for women with chronic 
hypertension, chronic kidney disease and no pre-existing disease at 20+0-33+6 weeks’, 20+0-36+6 weeks’, and 
20+0-40+6 weeks’ gestation for low PlGF, sFlt-1 and sFlt-1:PlGF as a prognostic indicators at time of sampling 
for subsequent delivery within 14 days for superimposed pre-eclampsia. 
Sampling gestation 
(weeks) 20
+0
-33+6 20+0-33+6 20+0-36+6 20+0-36+6 20+0-40+6 20+0-40+6 
 CKD or CHT No pre-existing disease CKD or CHT 
No pre-existing 
disease CKD or CHT 
No pre-existing 
disease 
Number of women 
(Cases) 61 (14) 155 (49) 94 (25) 289 (103) 123 (61) 456 (253) 
ROC (SE) for PlGF 0.84 (0.09) 0.91 (0.02) 0.82 (0.06) 0.84 (0.02) 0.79 (0.05) 0.79 (0.02) 
ROC (SE) for sFlt-1 0.79 (0.09) 0.88 (0.02) 0.79 (0.06) 0.81 (0.02) 0.77 (0.04) 0.77 (0.02) 
ROC (SE) for sFlt-1:PlGF 0.84 (0.09) 0.91 (0.02) 0.83 (0.06) 0.86 (0.02) 0.80 (0.05) 0.81 (0.02) 
 
ROC: Receiver Operator Curve; SE: Standard Error; CKD: Chronic kidney disease; CHT: Chronic 
hypertension; PlGF: Placental Growth Factor; sFlt-1: soluble fms like tyrosine kinase receptor-1 
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Supplementary Table 12: Validation cohort: Test performance statistics for sFlt-1:PlGF Ratio >85  as a 
prognostic indicator at time of sampling for subsequent delivery within 14 days for superimposed pre-eclampsia 
at 20+0-36+6 weeks and 20+0-40+6 weeks in women with chronic kidney disease and/or chronic hypertension 
sFlt-1:PlGF >85 
 
No pre-existing Disease 
N=456 
Chronic Hypertension 
N=94 
Chronic Kidney Disease 
N=29 
20+0-33+6 weeks    
Sensitivity %  
(95% CI) 
n/N  
91.8      
(80.4-97.7) 
45/49 
100.0      
(47.8-100.0) 
5/5 
90.0      
(55.5-99.7) 
9/10 
Specificity %  
(95% CI) 
n/N 
81.1      
(72.4- 88.1) 
86/106 
80.5      
(65.1-91.2) 
33/41 
80.4      
(66.9-90.2) 
41/51 
Positive Predictive Value % (95% CI) 
n/N 
69.2      
(56.6-80.1) 
45/65 
38.5      
(13.9-68.4) 
5/13 
47.4      
(24.4-71.1) 
9/19 
Negative Predictive Value % (95% CI)  
n/N 
95.6     
(89.0-98.8) 
86/90 
100.0      
(89.4-100.0) 
33/33 
97.6      
(87.4-99.9) 
41/42 
Positive likelihood ratio  
(95% CI) 
4.87       
(3.25-7.29) 
5.13       
(2.75-9.54) 
4.59       
(2.54-8.30) 
Negative likelihood ratio  
(95% CI) 
0.10       
(0.04-0.26) 
0.00 
- 
0.12       
(0.02-0.80) 
 
   
20+0-36+6 weeks    
Sensitivity % (95% CI) 
n/N  
85.4      
(77.1- 91.6) 
88/103 
90.9    
  (58.7- 99.8) 
10/11 
78.9    
  (54.4-93.9) 
15/19 
Specificity % (95% CI) 
n/N 
71.5      
 (64.4-77.9) 
133/186 
76.3     
 (63.4-86.4) 
45/59 
76.0     
 (64.7-85.1) 
57/75 
Positive Predictive Value % (95% CI) 
n/N 
62.4      
 (53.9-70.4) 
88/141 
41.7      
(22.1-63.4) 
10/24 
45.5    
  (28.1-63.6) 
15/33 
Negative Predictive Value % (95% CI) 
n/N 
89.9      
 (83.8-94.2) 
133/148 
97.8      
(88.5-99.9) 
45/46 
93.4   
   (84.1-98.2) 
57/61 
Positive likelihood ratio (95% CI) 3.00        
(2.36-3.82) 
3.83       
(2.34-6.28) 
3.29     
  (2.07-5.24) 
Negative likelihood ratio (95% CI) 0.20       
 (0.13-0.33) 
0.12      
 (0.02-0.78) 
0.28    
   (0.11-0.67) 
 
   
20+0-40+6 weeks    
Sensitivity % (95% CI) 
n/N  
83.5    
   (77.2-88.7) 
147/176 
83.3     
 (58.6-96.4) 
15/18 
75.0     
 (55.1-89.3) 
21/28 
Specificity % (95% CI) 
n/N 
65.2     
  (59.3-70.8) 
182/279 
73.7   
   (62.3-83.1) 
56/76 
74.7      
(64.8-83.1) 
71/85 
Positive Predictive Value % (95% CI) 
n/N 
60.2    
   (53.8-66.4) 
147/244 
42.9  
   (26.3-60.6) 
15/35 
46.7   
   (31.7-62.1) 
21/45 
Negative Predictive Value % (95% CI) 
n/N 
86.3     
  (80.9-90.6) 
182/211 
94.9    
  (85.9-98.9) 
56/59 
91.0    
  (82.4-96.3) 
71/78 
Positive likelihood ratio (95% CI) 2.40    
    (2.02-2.86) 
3.17   
    (2.06-4.86) 
2.97    
   (1.98-4.46) 
Negative likelihood ratio (95% CI) 0.25     
   (0.18-0.36) 
0.23    
   (0.08-0.64) 
0.33   
    (0.17-0.64) 
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